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SUMMARY
Reactive oxygen species (ROS) have been shown to mediate the effect of
several growth factors such as angiotensin II (Ail), epidermal growth factor
(EGf) and platelet-derived growth factor (PDGF). Endothelin-1 (ET-1) is an
important growth factor for vascular smooth muscle ceils (VSMC) which is
beheved to contribute to the pathogenesis of vascular abnormalities such as
atherosclerosis, hypertension and cardiac hypertrophy. However, a possible role
of ROS generation in mediating the ET-1 response on ERK1/2 and PKB, key
components of growth promoting and proliferative signaling pathways, has flot
been examined in detail. Therefore, the aim of the present study was to
investigate the involvement of ROS in ET-1-mediated activation of ERK1/2 and
PKB as well as Pyk2 in A-10 VSMCs. These cefis are obtained from rat
ernbiyonic thoracic aorta. Pyk2 is a non-receptor Ca2-dependent protein
tyrosine kinase and an upstream regulator of MAPK signaling. ET-1 stimulated
the phosphorytation of ERKÎ/2, PKB and Pyk2 in a dose and time-dependent
fashion with maximum response being elicited at 10 nM winch peaked at 5 min.
Treatment of VSMC with ET-1 resulted in an increase in the generation of ROS
that could be blocked with diphenyleneiodonium (DPI), an inhibitor ofNADPH
oxidase. furthermore, DPI pretreatment of ceils prior to stimulation with ET-1,
attenuated ET-1 enhanced phosphorylation of ERK1/2, PKB and Pyk2. N
acetylcysteine (NAC), another ROS scavenger, also exhibited a sirnilar
response. Moreover, DPI caused a decrease in the protein synthesis stimulated
by ET-1. These resuits demonstrate that ROS is a critical mediator of ET-1-
induced signaling events linked to hypertrophic and growth promoting pathways
inVSMC.
There is an emerging evidence suggesting that nitric oxide (NO), a
vasoactive substance, contributes to the regulation of several hormone-mediated
responses such as EGF, PDGF as well as ET-1 and exerts an anti-mitogenic and
anti-proliferative effect in vitro. However, the mechanism by winch NO
iv
antagonizes ET-1 effect remains unknow. Therefore, the aim ofthis study was to
determine if NO generation would modify ET-1 -induced signaling pathways
involved in cellular growth and proliferation in A-10 VSMC. NO effect has been
evaluated by measuring phosphorylation levels of ERKY/2, PKB and Pyk2 by
immunoblot. Treatment of A-10 ceils with S-nitroso-N-acetylpenicfflamine
($NAP), a NO donor, attenuated the ET-1-enhanced phosphorylation of
ERK1/2, PKB and Pyk2. Since, NO mediates principally its effect through a
cycic GMP/soluble guanylate cyclase pathway, we investigated the role of 8-
Br-cGMP, a non-metabolizable and ceil permeable analogue of cGMP, winch
exhibites a sirnilar effect to SNAP on ET-1-induced ERK1/2, PKB and Pyk2
phosphorylation. Furthermore, ODQ, an inhibitor of guanylate cyclase activity,
reversed the inhibitory effect of NO on ET-1-induced responses. SNAP also
appeared to decrease the protein synthesis induced by ET-1. Taken together,
these data demonstrate that NO attenuates selectively ERK1/2, PKB and Pyk2
phosphorylation induced by ET-1 via cGMP, winch antagonize the growth
promoting and proliferative effects of ET-1.
Key words: ET-1, ROS, NO, MAPKs, ERK1/2, PKB, Pyk2, A-10 ceils.
VSOMMAIRE
Les espèces réactives oxygénées modulent l’effet de plusieurs facteurs de
croissance comme l’angiotensine II (AIT), l’EGF (“epidermal growth factor”) et
le PDGf (“platelet-derived growth factor”). L’endotheline-l (ET-1) est un
important facteur de croissance pour les cellules du muscle lisse vasculaire
(“V$MC”) et contribue aux anormalités vasculaires, entre autre,
l’athérosclérose, l’hypertension ainsi que l’hypertrophie cardiaque. La
génération des espèces réactives oxygénées pourraient aussi jouer un rôle dans
l’activation des voies de signalisation activées par l’ET-l, en particulier
l’activation de ERKT/2 et de PKB. Ces deux composantes clés sont impliquées
dans la croissance et la prolifération cellulaire. Ainsi, le but de la présente étude
est d’évaluer la participation des espèces réactives oxygénées dans l’activation
de ERK1I2, PKB et Pyk2 induite par ET-1 dans les “VSMC” de lignée A-10.
Ces cellules sont obtenues à partir de l’aorte thoracique embryonnaire de rat.
Pyk2 est une protéine tyrosine kinase dépendante du calcium et constitue ainsi
un régulateur ascendant de la voie de signalisation des MAPKs. ET-1 a permis
de stimuler la phosphorylation de ERK1/2, PKB et Pyk2 de façon dépendante de
la concentration et du temps d’où une réponse maximale a été obtenue à 10 nM
et après une stimulation de 5 min. Le traitement des “VSMC” avec ET-1 a
augmenté la production des espèces réactives oxygénées, alors qu’une
diminution a été observée en présence du diphenyleneiodonium (DPI), un
inhibiteur de la NADPH oxydase. En outre, le prétraitement des cellules avec
DPI a permis d’atténuer la phosphorylation de ERK1/2, PKB et Pyk2 induite par
ET-1. Une réponse similaire a été observée en utilisant un autre antioxidant, le
N-acetylcysteine (NAC). De plus, DPI a inhibé la synthèse protéique stimulée
par ET-1. Ces résultats démontrent que les espèces réactives oxygénées sont des
médiateurs importants dans l’activation des composantes de la voie de
signalisation de ET-1, ce qui contribue à la croissance et à l’hypertrophie
cellulaire.
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Il a été suggéré que l’oxyde nitrique (NO), une substance vasoactive,
contribue à la régulation des réponses induites par plusieurs hormones comme
l’EGF, le PDGf et l’ET-l en exerçant un effet anti-mitogénique et anti
prolifératW in vitro. Cependant, le mécanisme par lequel NO antagonise l’effet
de ET-1 est à ce jour inconnu. Le but de cette étude est donc d’évaluer si la
génération de NO pourrait modifier les composantes de la voie de signalisation
de ET-1. L’effet de NO a été déterminé en mesurant les niveaux de
phosphorylation de ERK1/2, PKB et Pyk2 à l’aide d’immunobavardage. Le
traitement des cellules A-10 avec S-nitroso-N-acetylpenicifiamine (SNAP), un
donneur de NO, a permis d’atténuer la phosphorylation de ERK1/2, PKB et
Pyk2 induite par ET-1. Comme NO médie principalement son action par la voie
de GMPc/guanylate cyclase soluble, on a donc étudié le role du $-Br-GMPc, un
analogue du GMPc non-métabolisable et perméable à la cellule. Un effet
similaire à celui de SNAP a été observé. En outre, ODQ, un inhibiteur de
l’activité de la guanylate cyclase, a renversé l’effet de NO sur la
phosphorylation des composantes de signalisation stimulées par ET-l. SNAP a
permis aussi de diminuer la synthèse protéique induite par ET-1. Finalement, les
résultats démontrent que NO atténue sélectivement la phosphorylation de
ERK1/2, PKB et Pyk2 de la voie de signalisation de ET-1 par l’intermédiaire du
GMPc, ce qui antagonise les effets de ET-l soit la croissance et la prolifération
cellulaire.
Mots des: ET-l, ROS, NO, MÀPKs, ERK1I2, PKB, Pyk2, A-10 ceils.
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CHAPTER 1
INTRODUCTION
21.1 Endothelin
Endothelin, one of the most potent vasoconstrictors, was discovered by
Yanagisawa and co-workers (1) in 1988. It was characterized and cloned from
porcine aortic endothelial ceils (1) and exerts inotropic and mitogenic properties,
influences homeostasis of sait and water and stimulates the renin-angiotensin
aldosterone and sympathetic nervous systems (2,3,4). In fact, the overail effect
of the actions of endothelin is usually to increase vascular tone and biood
pressure. Endothelin also play an important role in the pathophysiology of
cardiac, vascuiar and renal diseases associated with regional or systemic
vasoconstriction (5) such as hypertension and atherosclerosis.
1.2 Structures of endothelins
Endothelin (ET) is a 21 aminoacid peptide winch exists in at least three
isoforms: ET-1, ET-2 and ET-3 (6,7). Ail ET isopeptides share a common
structure: two disuffide bonds (Cys’-Cys’5 and Cys3-Cys”), a cluster of tbree
polar charged side chains on aminoacid residues s-10 and a hydrophobic C-
terminus (residues 16-21) containing the aromatic indole side chain at Trp21.
ET-2 contains two aminoacid substitutions (Trp6-Leu7) and shares 90%
sequence homology with ET-1. ET-3 contains six aminoacid substitutions (Thr2,
Phe4-Thr5-Tyr6-Lys7 and Tyr’4) and shares 71 % sequence hornology with ET-1
and ET-2 (8,9). The hydrophobie C-terminus of ET is essential for its
3bioactivity, as well as the ioop configuration (9). ETs share close sequence
homology (- 67%) and similar bioactivities with the sarafotoxins, a group of
peptide toxins isolated from venom of some scorpions and snakes (8). The
disulfide bonds, polar side chains and hydrophobic C-terminus of ETs are
largely conserved in sarafotoxins (9) (Fig. 1.1).
NH3 Endothelin-1
EndotheUn-2
Endothelin-3
Figure 1.1 : Structures of endothelins. Dark circles indicate where
aminoacids differ from those ofendothelin-1. (Based on ref t$Î)
41.3 Molecular genetics and regulation of generation of endothelin
Each member of the endothelin family possesses a separate gene that
encodes a specific precursor for the mature isoform (5). The 5’ upstrearn
promoter region of the genes contains binding sites for activating protein 1 and
nuclear factor 1, which are involved in transcriptional induction of mRNA for
endothelin- 1 by angiotensin II and transforming growth factor 3 (5,10). The 3’
untranslated region (3’-UTR) of the mRNA contains adenine-uracil-rich (AU
rich) sequences that regulate the stability of preproendothelin- 1 mRNA (5).
Generation of endothelin-1 is induced by many stimuli, including vasoactive
hormones, growth factors, hypoxia, shear stress, lipoproteins, free radicals,
endotoxin and cyclosporin (11) (Fig. 1.2). Production of endothelin-1 is
inhibited by stimuli that act to increase intracellular level of cyclic guanosine
monophophate (cGMP), including endothelium-derived nitric oxide,
nitrovasodilators, natriuretic peptides, heparin and pro staglandins (11).
5Hormones
Angiotensm II
Insuim
Vasopressm
Cortisol
Peptides
Cytokines
Endotoxm
Endotheim
TGFf3 \\\\
Physico-chemical
Stimuli
Hypoxia
Shear stress (low)
‘j.
ET-1
Inhibition
Prostacyclin
Shear stress (high)
Nitric oxide
Heparm
ANP, BNP, CNP
Ï
Figure 1.2 Regulation of ET-1 synthesis and its pathway of generation.
ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; CNP =
C-type natriuretic peptides; a.a = aminoacids. (Based on ref 5)
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61.4 Biosynthetic pathway
The initial product of the human endothelin- 1 gene is preproendothelin- 1,
a 212 aminoacid immature peptide (Fig. 1.2). Preproendothelin-1 is
proteolytically cleaved by a furin-like enzyme to form biologïcally inactive
intermediate, a 3$-aminoacid peptide termed big endothelin-1 (1,5). A protease
called, endothelin-converting enzyme (ECE), then cleaves Trp21-Va122 of big
endothelin-1 to form the mature 21-aminoacid ET-1 peptide (1,5,13). Processing
of big ET-1 to ET-1 is essential for its biological activity (1,5,14). Endothelin is
secreted by a constitutive pathway, but evidence also suggested that in some
ceils endothelin can be secreted by a pathway via secretory granules (15). The
pathway of secretion involves the rough endoplasmic reticulum, golgi cisternae,
golgi small exocytic vesicles directly beneath the plasma membrane (15).
1.5 Sites of eneration
Endothelial ceils are the major site of generation of endothelin- 1, tins
tightly correlates with the high expression levels of mRNA for
preproendothelin- 1 and the presence of intracellular converting enzyme in these
ceils (6,8,12). Human aortic vascular smooth muscle ceils express mRNA for
endothelin-1, but its production is 100 fold less than that in endothelial ceils (5).
Also, endothelin- I is produced by the afrway epithelial ceils, macrophages,
fibroblasts, cardiomyocytes, posterior pituitaly and central nervous system
7(6,8,11). Endothelin-2 is produced by the kidney and intestinal epithelial cefis,
and endothelin-3 by brain neurons and renal tubular epithelial cefls (6,8).
1.6 Plasma concentrations ofendothelins
Plasma concentrations of ET-1 is in the range 1-10 pmoVL in healthy
subjects (5,6). Plasma ET-2 and ET-3 are found at even Iower concentrations
(6). Therefore, under normal physiological conditions, endothelins are flot
circulating hormones; rather they act as autocrine and paracrine factors at
multiple sites in the body (6).
1.7 BioIoical actions ofendothelin-1
When injected in vivo, ET is the most potent vasoconstrictor agent yet
identffied (1,9) particularÏy in the brain (16), renal (17) and pulmonary
vasculature (18,19). Intraventricular injection of ET-1 induces a transient
increase in arterial pressure, respiratory rate and renal sympathetic nerve activity
followed by a long-term depression of these parameters (6,20). While,
intravenous bolus administration of ET-1 in different species leads to a short
lived decrease in vascular resistance followed by the long-term increase,
implicating a balancing act of dilator and pressor ffinctions for endothelins (6).
ET-1 exerts a positive chronotropic (21) and inotropic (22) action on human
heart, and also mediate cardiac hypertrophy (23) and rernodeling in congestive
$heart failure through its mitogenic properties (24). ET-1 has also mitogenic
effects on smooth muscle ceils (25), fibroblasts (26), macrophages (27),
mesangial ceils (31), and increases as well ceil proliferation (28,29,30,31).
1.8 Endothelin receptors
Endothelins exert their biological actions through the activation of two
receptor subtypes, ET-A and ET-3 (14,32). Both receptors beÏong to a large
family of transmembrane guanine nucleotide-binding protein-coupled receptofs
(GPCRs) (33). They contain seven transmembrane domains of 22-26
hydrophobic aminoacids in their --400-aminoacid sequences (14,32). Thefr N-
terminal region is extracellular and their C-terminal region is intracellular (7).
Type A receptors exist mainly in vascular smooth muscle ceils but is also found
in cardiomyocytes, fibroblasts, hepatocytes, adipocytes, osteoblasts and brain
neurons (22,3 2,34) and present higher affinities for ET-1 and ET-2 than for ET-
3 (6,14). Type B receptors exist predominantly in endotheial ceils and smooth
muscle ceils but is also found in cardiomyocytes, hepatocytes, fibroblasts,
osteoblasts, different epithelial celis and neurons (22,32,34) and have equal
subnanomolar affinities for ail endothelin peptides (6,14). Therefore, ET-1
binding to ET-A and ET-B receptors on srnooth muscle produces
vasoconstriction, celi growth and cefi adhesion (14,35). The binding of ET-1 to
endotheial ET-B receptors stirnulates the release of NO and pro stacydlin winch
9prevents apoptosis, inhibits ECE-1 expression in endothelia] celis and plays an
important role in ET-1 clearance (14,35).
1.9 Activation ofthe phosphoïnositide cascade by ET-1
following the binding of ET-1 b ils receptor, the hormone-receptor
complex activates Gq-protein which is the best characterized signaling
interaction with ET-A receptor (6,7). As with ail heterotrimeric G-proteins, Gq
consists of an Œ-subunit (aq, or related a-subunit, such as al 1), a member ofthe
-subunit family as weil as a member of the y-subunit family and is associated to
the membrane (36) (Fig. 1.3). In the inactive Gq heterotrimer, aq is ligated to
GDP. Exchange of GDP for GTP on aq leads to the dissociation of aq(GTP) and
y and both remain associated with the membrane (33). Thefr dissociation leads
to activation of phosphoinositide-specific phospholipase C (PLC ) (37,3$),
winch then hydrolyzes the membrane phospholipid, phosphatidylinositol-4’,5’-
bisphosphate [Ptdlns(4,5)P2J to two second messengers: hydrophobic
diacylglycerol (DAG), winch remains in the plane of the membrane, and soluble
inositol- 1 ‘,4’,5 ‘-trisphosphate [Jns( 1 ,4,5)P3J (37,3$). Ins( 1 ,4,5)P3 diffuses into
the cytoplasm and activates some calcium channels of the sarcoplasmic
reticulum, winch leads 10 an increase of Ca2 levels in the sarcoplasma and ceil
contraction (7,8). DAG together with Ca2 activates the phosphatidylserine
dependent protein kinase, protein kinase C (PKC) (39) (Fig. 1.3).
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Figure 1.3 : Special case of Gq-protein-coupled receptor in intracellular
signaling. (1) The binding of an agonist to a surface receptor, R, activates
phospholipase C through the intermediacy of what is shown here as (2) a Gq
protein. Phospholipase C catalyzes the hydrolysis of PIP2 to 1P3 and DG (3). The
water-soluble 1P3 stimulates the release of Ca2 sequestered in the endoplasmic
reticulum (4) winch in tum activates numerous cellular processes through the
intermediacy of calmodulin and its homologs (5). The non-polar DG remains
associated with the membrane, where it activates protein kinase C to
phosphorylate and thereby modulate the activities of a number of cellular proteins
(6). Tins latter activation process also requires the presence of the membrane lipid
phosphatidylserine (PS) and Ca2. PIP2 = phosphatidylinositol bisphosphate; 1P3
inositol triphosphate; DG = diacylglycerol. The green circles fflustrated in the
figure do flot apply to the special case of Gq-protein-coupled receptor. (Based on
ref 134)
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PKC is a family of serine/threonine kinases that is subdivided into three
groups. The classicai or conventionnai PKCs winch require DAG and Ca2
include the isoenzyrnes ci, f3 and ‘ (40). Novel PKC (nPKC) where the activities
are DAG-dependent though probably Ca2tindependent include the isoenzymes
, g, r, O, a and y and atypical PKC (aPKC) are independent of DAG and Ca2
and include and 7. isoenzymes (39).
1.10 Mechanisms ofET-1-induced activation ofMAPK cascade
The next process associated with exposure to ET-1 is the activation of a
member of the small GTP-binding protein family, Ras winch involves exchange
of GDP for GTP (41). Once activated, Ras-bound to membrane recruit the first
member of the mitogen-activated protein kinases (MAPK) calied Raf or
MAPKKK (42,43). Raf phosphorylates MEK/MAPKK at specilic
serine/threonine residues, winch in turn, phosphorylates ERK1/2 (MAPK42/44)
on threonine and tyrosine residues (42,43). MAPK are serine/threonine protein
kinases, winch are also activated in response to a variety of extemal stimuli such
as growth factors, hormones and stress (23,42,43). In a variety of ceil types,
activation of ERK1/2 leads to the phosphorylation of downstream cytosolic
regulatory proteins, such as p90’ winch phosphorylates ribosomai proteins and
participates in protein synthesis (44) (Fig. 1.4). Mso, ERK1/2 migrates from the
cytosoi to the nucleus and phosphorylates many transcription factors winch lead
to activation ofgenes invoÏved in growth and differentiation (181) (Fig. 1.4).
n12
Figure 14 : Schematic model showing key steps in ET-1-induced activation
of MAPK and PI-3KIPKB signaling. PTKs = protein tyrosine kinases.
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13
Several reports have demonstrated that ET-1 activates ERK1/2 signaling
pathway in many ceil types including cardiomyocytes (45), fibroblasts (2$),
glomerular mesangial ceils (31) and vascular smooth muscle ceils (VSMC) (46).
Activation of the ERK1/2 cascade is the best characterized. Although, ]NK and
p3$mapk are most strongly activated by cytotoxic cellular stress and are better
classffied as stress-activated protein kinases (SAPK). ET-1 also activates JNK
(c-Jun-NH2 terminal kinase) and p3 $mapk cascades to a lesser degree than ERK
in cardiomyocytes (45,47), VSMC (4$) as well as in mesangial ceils (49). In
addition, several other smafl G-protein families have been stimulated including
Rho, Rab and Ran (41). ET-1 activates members of the Rho family in
cardiomyocytes (50) and fibroblasts (51) which are positive regulators of
p3$mapk pathway (52). The remaining smafl G-proteins and thefr expression
characteristics have flot been investigated systenmticafly.
There is some evidence supporting the involvement of PKC in Ras
activation in many ce!! types including cardiomyocytes (53) and rat myometrial
celis (40). The nature of the connection between the two processes is obscure
and other pathways may operate. A possible role of a calcium-regulated
cytop!asmic proline-rich tyrosine kinase 2, Pyk2 (also known as related
adhesion focal tyrosine kinase (RAFTK), focal adhesion kinase-2 (FAK-2) and
ceil adhesion kinase [3 (CAK [3), calcium-dependent tyrosine kinase (CADTK)),
in the activation of MAPK has been suggested in primary astrocytes (54,55) and
rat kidney mesangial ceils (56). In severa! other ceil types, the Ca2- and PKC
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dependent Pyk2 activation (40,57) has been shown to link GPCRs to upstream
regulators of ERK1/2 MAPKs, such as Src, Shc, Grb2, son of the sevenless
(SOS) and the Ras guanosine nucleotide exchange factor (27,56,58,59).
Previous data had shown that ET-1 -induced association of Pyk2 through the
binding of its autophosphorylated Tyr-402 to the SH2 (Src-homology 2) domain
of c-$rc lead to c-Src activation in many ceil types including mesangial cefis
(56,5$) and cardiomyocytes (47,56,60). Activated c-Src bound to Pyk2 rnight
directly phosphorylate adjacent cellular proteins, such as pl3OCas. Once
tyrosine-phosphorylated, pl3OCas has been shown to act as docking protein to
recruit its effectors able to activate JNK (61,62) in cardiomyocytes (47).
Evidence suggested that ET-1 mediates EGf receptor (EGFR)
transactivation winch predominantly contributes to ERK activation, while Pyk2
contributed less in cardiomyocytes (60). Both kinases activation are mediated
tbrough PKC signaling (60). Conversely, a recent report demonstrated that ET
1-induced JNK activation is preferentially regulated by Pyk2, c-Src and the
pl3OCas/Crk complex but flot by EGfR (47). However, the regulation of
transactivation of EGFR is signfficantly different arnong ceil types. In VSMC,
EGFR transactivation has been shown to mediate the angiotensin II-induced
ERK activation (63). ET-1-induced transactivation of EGFR contributes to the
activation of Shc adapter molecule, leading to its interaction with Grb2 (64),
winch could then associate with SOS. $hc-associated Grb2ISOS induces
exchange of GDP for GTP on Ras (59) and ultimately activate ERK signaling
15
(60,65). However, the invoïvement of Pyk2 in ET-1-induced signaling in
VSMCs has flot been yet deflned.
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1.11 Phosphatidylinositol-3 kinase cascade
Mother effector of Ras species, phosphatidylinositol-3 kinase (PI-3K) is
an enzyme that is implicated in a myriad of celiular processes. PI-3K activity
has been Iinked to cefi growth and transformation, differentiation, motffity and
survival (66,67). Ihe PI-3K group of lipid kinases catalyze the transfer of
phosphate from ATP to the 3’position of the inositol ring of the membrane
localized phosphoinositides. PI-3K phosphorylates at least three substrates:
phosphatidylinositol (Ptdlns), phosphatidylinositol-4-phosphate (Ptdlns-4-P)
and phosphatidylinositol-4,5-bisphosphate (Ptdlns-4,5-P2) and generates the
reaction products: Ptdlns-3-P, Ptdlns-3,4-P2 and Ptdlns-3,4,5-P3 respectively
(68). These phospholipids act as second messengers to activate several proteins
like PDK, PKB/Akt and p7OS6K (67,6$).
1.11.1 Classification ofPI-3Ks
PI-3Ks are divided into three classes based on their structure and
mechanism of regulation (69). Class I PI-3Ks generate Ptdlns-3-P, Ptdlns-3,4-
P2, Ptdlns-3,4,5-P3 and are activated by receptor tyrosine kinases and G-protein
coupled receptors (70). Class II PI-3Ks generate Ptdlns-3-P and Ptdlns-3,4-P2
and possess a lipid binding domain, whereas, Class III PI-3Ks generate Ptdlns
3-P only (70). Ptdlns-3-P is constitutively present in ail ceils and its levels do
not change following stimulation (70).
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1.11.1.1 Class I PI-3Ks
Class I PI-3Ks are famfly 0f heterodimeric proteins, each of which
consisis of a catalytic subunit of 110-120 kfla and a regulatory subunit of $5
kDa (66). Three mammalian catalytic PI-3Ks sharing 42-48% aminoacid
sequence identity have been cloned and are designated pli OŒ, pli 013, pli 06.
Each of these proteins interacts with the p85 regulatory subunits at the N-
terminal region, and contains a domain that binds to the smafl G-protein Ras, a
«PIK domaim> homologous to a region found in other phosphoinositide kinases
and a C-terminal catalytic domain (66,68). The catalytic p110 subunit possesses
both intrinsic kinase serine/threonine and phosphoinositide kinase activities
(69,71).
Two isoforms of p85, p$5Œ and p$5f3, have been purffied and cloned
(71,72). P85 subunits do flot possess any known enzymatic activity but are
composed of several domains with homology to those found in other docking
proteins. P85a and p85J3 contain an N-terminal Src-homology 3 (SH3) domain,
two or three proline-rich segments, a region of homology to GTPase-activating
proteins for the rho family of small G proteins (rho-GAPs) and two Src
homology 2 (SH2) domains (71). The inter-SH2 domain located between the
two SH2 domains is necessary and sufficient for interaction with the N-terminal
ofpllO catalytic subunits (71,72).
1$
1.11.2 Protein kinase B signaIin pathway
Several targets of PI-3K have been identffied, however, most widely
studied target is protein kinase B (PKB), also known as Akt ta product of akt
proto-oncogene). PKB is a serine/tbreonine kinase and three isoforms have been
identilied in mammalian system: PKBŒIAkt1, PKB[3/Akt2 and PKB1’/Akt3
(67,73,74). They are activated by dual phosphorylation on threonine (Thr308) and
serine (5er473) residues (73). AIl family members contain a central kinase
domain with specfficity for serine or threonine residues in substrate proteins
(73,74). N-terminal of PKB possesses a pleckstrin homology (PH) domain that
binds phospholipids. A short glycine-rich region that bridges the PH domain to
the catalytic domain follows the PH domain. The C-terminus of PKB is
hydrophobie and possesses a proline-rich domain (75).
The lipid products of PI-3K bind with high affmity and specfficity to the
PH-domain ofPKB with a preference ofPtdlns-3,4-P2 over Ptdlns-3,4,5-P3 (76).
Tins binding induces transiocation of PKB to the plasma membrane where
phosphorylation of Thr3O$ by Ptdlns-3,4,5-P3 dependent protein kinase-1
(PDK-1) and Ser473 by the hypothetical site PDK-2 is required for the
activation of PKB (76). Phosphorylation of both sites is mitogen- and PI-3K-
dependent (76). Several different targets of PKB have been identffled and
include members ofthe apoptotic cascade such as Bad (73,75), caspase (77) and
glycogen synthase kinase 3 (G$K-3) (7$) (Fig. 1.4).
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In mesangial ceils, ET-1 receptor activation has been shown to stirnulate
PI-3K phosphorylation through Ras (59). Also, in rabbit internai carotid artery
vascular smooth muscle ceils (ICA V$MCs), PI-3K appeared to be involved in
ET-1-induced Pyk2 tyrosine phosphorylation (79). Conversely, studies using
angiotensin II (Ail), a vasoactive peptide with similar effects to ET-1, have
suggested that Pyk2 regulates PI-3K cascade specffically via interaction of
Pyk2 with pl3OCas winch lead to their association with PI-3K in VSMC (65).
Recently, ET-I has been shown to slightly increase PKB phosphorylation in
cardiomyocytes (80). However, no direct activation ofPKB in response to ET-1
has been demonstrated in VSMC.
1.12 Role of endothelin in cardiovascular diseases
1.12.1 Endothetin in human hypertension
The haDmark of hypertension is an increase in peripheral vascular resistance
winch is considered to be related to an increase in tone of resistance arteries as
well as to structural changes or vascular remodeling ofthe blood vessels ($1,82).
Several forms of hypertension are mediated by high endothelin (ET) levels in the
circulation or by alterations in response to ET at the receptor level ($2,83).
Besides the abifities of ET to increase vascular tone, it also induces hypertrophy
in smooth muscle ceils and fiinctions as mitogen as well (8 1,84,85) (Fig. 1.5).
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Enhancement of generation of endothelin- 1 (ET-1) plays a rote in
hypertrophic remodeling of arteries in moderately to severely hypertensive
patients ($3). Also, this enhancement of ET-1 generation contributes to elevate
blood pressure and may explain the reduced responsiveness of arteries to ET-1
through downregulation of ET receptors. Recently, it lias been shown that sait-
sensitive hypertensive patients oflen have Iow plasma renin activity and thefr
endothelin in plasma responds in an exaggerated fashion with an increase afier
sodium depletion, in association with enhanced plasma catecholamines ($6).
This suggests a reiationship of the sympathetic system, sodium sensitivity and
reactivÏty of the endothelin system that may contribute to blood pressure
elevation in these subjects (81,82,87).
Proliferative effects of ET have been demonstrated in vascular smooth
muscle ceils (81,84,88) as well as in renal ceils such as mesangial ceils
(81,88,89). Thus, the capacity of endothelin to regulate contractile responses and
proliferation of vascular smooth muscle and its capacity to profoundly affect
renal ffinction make it a primary candidate as a mediator of hypertension.
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1.12.2 Endothelin in experimental hypertension
Most hypertensive animal models have normal or only silghtly increased
plasma endothelin levels (90). $everal studies have reported that in
deoxycorticosterone acetate (DOCA)-salt and aldosterone-sait hypertensive rats
(91,92), DOCA-salt treated spontaneously hypertensive rats (SHR) (93), DaM
sait-sensitive rats (94), one-kidney-one-chp Goldblatt hypertensive rats (95) and
stroke-prone SHR (96), there is overexpression of preproET- 1 mRNA in the
endotheium (97). In SHR (91,93,98), endothelin doesn’t seem to play an
important role, although increased vasoconstrictor response to ET-1 has
occasionally been reported in SHR (99).
Elevated vessel ET mRNA mediate structural effects such as vascular
hypertrophy due to its growth promoting properties (82). DOCA-sait
hypertensive rat arteries show severe vascular hypertrophy with prorninent
medial thickening (100) and overexpression of the ET-1 gene (101). However,
in SHR, littie vascular hypertrophy and no ET-1 gene expression are reported
(102). Overail, it seems that in the DOCA-salt hypertensive rat and in rats with
malignant hypertension, ET plays a more important role than in other models.
Tins suggests that ail animal hypertensive models are not the same. The different
hypertensive diseases have different etiologies in winch endothelin plays
different roles, but in more severe forms of hypertension, such as malignant, ET
plays a clear central role.
23
1.12.3 Endothelin in atherosclerosis
Atherosclerosis involves injury of endotheial ceils, inflammation with
macrophage and monocyte infiltration of the vessel wall, release of cytokines
and growth factors, migration of smooth muscle celis to the intima, and lipid
accumulation in foam ceils (82). Evidence lias recently accrued suggesting
involvement of ET-1 in these processes leading to atherosclerosis development
and progression ($2). ET-1 is chemoattractant for monocytes and macrophages
and acts as a comitogen for vascular smooth muscle ceils together with growth
factors (103,104). Plasma and tissue ET are elevated in proportion to the
extension of atherosclerosis in patients with advanced disease (105). ET-B
receptors are upregulated in atherosclerotic human coronary arteries (106).
However, no change in ET-A and ET-B proportions in the media of coronary
arteries was detected (107). Rossi et al. (108) showed that atherosclerotic and
hypertensive individuals exhibited increased immunoreactive ET in the arteries.
Many components of human atherosclerotic lesions such as endothelial ceils,
macrophages, and smooth muscle ceils express ET-1 (109). Mechanisms
whereby increased ET-1 may contribute to atherosclerosis include stimulation of
migration of smooth muscle ceils (110) into the intima of vessels, activation of
inflammation in the vessel wall by stimulating cytokines and by increasing
oxidative stress (111).
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1.13 Reactive oxygen species and its implications in ET-1 signaling
During the last few years, evidence has accumulated to suggest that the
generation of reactive oxygen species (ROS) play a crucial role in the
development and the progression of vascular dysftinction (112). Under oxidative
stress conditions, excessive endogenous formation of ROS overcomes cellular
antioxidant defence mechanisrns, which results in ROS-iriltiated modification of
lipids, proteins, carbohydrates and DNA (112). ROS are very srnall, rapidly
diffusible, highly reactive molecules and include hydroxyl radicals (0H),
superoxide anion (0/) and non-radical derivative such as hydrogen peroxide
(H202) (Fig. 1.6). Endogenously, the main source of ROS is the mitochondria
winch converts 1-2 % of consumed molecular oxygen into superoxide anion
(113). In VSMCs and endothelial ceils, NADHINADPH oxidases represent the
most important source of 0/ (114). NADPH oxidase catalyzes the NADPH
dependent reduction of oxygen to 0/, winch is converted to H202 either by a
protonation reaction or by the action of superoxide dismutase (SOD). H202 is
reduced to F120 by catalase or glutathion peroxidase. Under certain conditions
and in presence of metals, I-1202 can generate the extremely active 01f via
Fenton or Haber-Weiss reaction (115) (Fig. 1.6).
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figure 1.6 : Key steps in the production of reactive oxygen species.
NADPH oxidase is a multicomponent enzyme. Several isoforms have been
found in the vascular wall (114). The plasma membrane-associated
flavocytochrome b55$ consists of two subunits: gp9lphox and p22phox (114),
and is the key catalytic component responsible for the transfer of electrons from
NADPH to molecular oxygen (116). P47phox, p67phox and a smafl GTP
binding protein, Rac, are the cytosolic components that transiocate from the
cytosol to the membrane during NADPH oxidase assembly (117). ET-1 has been
shown to activate NADPH oxidase, thereby increasing O{ levels in endothelial
ceils (11$) and stimulates O2 production in pulmonary smooth muscle ceils
(119). Recent findings also suggest that ET-1 can increase 0f levels via
activation ofNADPH oxidase in DOCA-sait rats (120).Whereas, growth factors
such as AH and PDGf have been shown to generate ROS in VSMCs (114,121).
Increased ROS generation has bcen associated with a variety of
cardiovascular pathologies (122) including hypertension (123) and
atheroscierosis (124). Pathogenesis of cardiovascular diseases by activating
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ROS are thought to participate in the cellular signaling pathways responsible for
promoting ceil growth (125) and proliferation (30,126,127). It has been
demonstrated that ET-1 induces JNK and p38mapk activation through ROS
generation but not ERK1/2 (30). These flndings are consistent with those of Fei
et aL (128), who demonstrated that JNK activation but flot ERK1I2 activation by
ET-1 was signfflcantly inhibited by antioxidants in rat smooth muscle ceils.
Conversely, a recent study demonstrated the involvement of ROS in ET-1-
induced activation of ERKI/2 pathway as well as JNK and p3$mapk in cardiac
fibroblasts (127). However, the contribution of ROS in ET-1-induced ERKY/2
activation is controversial and remain to be claril’ in VSMC. In addition, ROS
have been shown to regulate PKB signaling pathway in human hepatorna ceil
(126) as well as in VSMC (115). But whether ROS stimulate PKB activity in
response to ET-1 has flot been yet elucidated. More evidence have suggested
that Pyk2 is activated in presence of 11202 (129). However, a possible role of
ROS in mediating the ET-1 response on Pyk2 and whether NADPH oxidase is
involved in the generation of ROS by ET-1 are questions that stifi need to 5e
answered.
1.14 Nitrïc oxide
Nitric oxide (NO) is a free radical that was previously described as a non
prostaglandiri, endothelium-derived relaxing factor (EDRF) (14,130,131) and is
involved in the regulation of a large number of biological processes (14,130).
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Initial efforts to understand the role of NO in the nervous, cardiovascular and
immune systems expanded to numerous cellular events and pathologies
including apoptosis, inflammation, kidney ffinction, diabetes, oxidative stress
and aging (131,132).
1.14.1 Formation of nitric oxide
NO is formed from the aminoacid, L-arginine, in an oxidative reaction that
consumes molecular oxygen and reducing equivalents in the form of NADPH
+(lil,132,133) (Fig. 1.7). Reaction products are NO, NADP and citruilme.
Since NO is a signaling hydrophobie molecule small enough to pass across the
target-ceil plasma membrane, NO cannot be stored and released as needed
(130,134). NO is produced by the enzyme nitric oxide synthase (NOS), by the
deamination of L-arginine. NOS is an enzyme requfring FAD, FMN, heme, Ca2,
calmodulin and 6(R)-tetra-hydro-L-biopterin (BI-I4) as cofactors (133) (Fig. 1.7).
NO acts locally because it has a short half-life (5-10 seconds) in the extracellular
space before it is converted to nitrates and nitrites by oxygen and water
(130,131,134).
Figure 1.7 : The nitric oxide synthase (NOS) reaction. CaM = catmoduhn;
Zn = Zinc. (Based on ref 135)
1.14.2 NOS isoforms
Three distinct NOS enzymes, each a product of a unique gene, have been
identffied and characterized (130,131,135,136). The neuronal form (nNOS or
NOS-1) is a Ca2-dependent enzyme found in neuronal tissue and skeletal
muscle. Four splice variants of full lengh nNOS (nNOSŒ) have been identffied
recently (nNOSf3, nNOSy, nNOSi and nNOS-2). The second isoform of NOS
(iNOS or NOS-2) is inducible in a variety of ceils and tissues in response to
cytokine or endotoxin activation. The third form, first found in vascular
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endothehal celis (eNOS or NOS-3), 15 also Ca -dependent, but differs from the
neuronal form by its smailer size. eNOS is rnyristoylated and palmitoylated at
the N-terminus. Those modifications are required to localize to the
plasmalemmal caveolae of endothelial ceils. Human enzymes exhibit
approximately 51-57 % homology at the aminoacid level (130,135).
Structuraily, ail NOS isozymes consist of a carboxy-terminal reductase dornain
winch binds the flavin cofactors. A Ca27ca1modu1in binding domain lies in the
center foilowed by an oxygenase domain where binding of heme, 02, BR1 and
arginine substrate take place (135).
1.14.3 Nitric oxide function
NO ceilular signaling involves the regulated synthesis of NO by eNOS in
the vascular endothelium, diffusion of NO into adjacent smooth muscle ceil and
activation of the soluble isoforrn of guanylate cyclase (sGC) (137). When NO
binds to the pentacoordinate ferrous heme of the sGC that appears to be
uniquely tuned to interact with NO, conformational changes occur in the
enzyme, stimulating the reaction (138). NO causes relaxation of the smooth
muscle by mediating the formation of cGMP that acts as a second messenger
and activates the cGMP-dependent protein kinases (protein kinase G) (137,139),
which in tum, facilitates the phosphorylation of various proteins as weil as the
reduction of intraceilular calcium concentrations by different mechanisms (140).
Moreover, NO also targets many proteins either by nitrosylation of thiol
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residues, nitration of tyrosine or oxidizing DNA and protehis (140). Increasing
evidence indicates also that NO may inactivate NADPH oxidase by inhibiting its
assembling process, thus reducing the ROS levels (141). In higher
concentrations, NO can react rapidly with superoxide (O2) to form peroxynitrite
(0N00), a potent oxidant with the potential to disrupt protein structures by
nitrating the protein tyrosine residues (142). Although NO signaling is complex
as a resuit of its interactions with ROS, heme groups on proteins, sullhydryl
groups, and other cellular targets, the activation of guanylate cyclase remains the
most important pathway in mediating NO function (137).
1.14.4 Guanylate cyclase
Guanylate cyclase is an enzyme that catalyses the conversion of the
guanosine triphosphate (GTP) to 3’-5’-guanosine monophosphate (cGMP). The
guanylate cyclase is found in many cellular compartments (140). Two major
forms of guanylate cyclase are known, the particular guanylate cyclase and the
soluble guanylate cyclase. It is generally conceded that activation of soluble
guanylate cyclase (sGC) is the principal intraceflular event that hiitiates
relaxation (143,144). The activity of the sGC is regulated by nitrovasodilators,
oxidation products of fatty acid and free radicals (134,145). sGC is a
heterodimer of two subunits a and 13. Each subunit is divided in three different
domains: the heme-binding domain, the catalytic domain and the dimerization
domain (145).
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N-terminal of each subunit contains heme as a prosthetic group winch
serves as a site for NO binding (145). sGC lacking the heme moiety, is flot able
to be activated by NO (145). Heme is attached to the protein portion of the
enzyme by an imidazole axial ligand and binding of the heme is specific to the [3
subunit ofthe N-terminal region (146,147). C-terminal ofeach subunit possesses
a catalytic domain with a high homology sequence between the monomers
(146,147). Coexpression of the catalytic domain of both subunits is necessary
for GC activity. There is the dimerization domain between both domains
described above that mediates the association of the heterodimer winch is
essential for the catalytic subunit (146,147). NO binding to the berne oftlie sGC
resuits in the formation of a complex penta-coordinate heme-nitrosyl that breaks
the axial histidine Iink (147). Tins conformational change exposes the catalytic
site to GTP, leading to the activation of the enzyme and conversion of GTP to
cGMP by sGC in the presence ofMg2 or Ï4n2 ions (137) (Fig. 1.8).
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1.14.5 Reulation ofcGMP production
In most tissues, the intracellular concentration of cGMP is
determined by the rate of formation which is regulated by agonist-induced
stimulation of a cyclase and hydrolysis of cGMP by a related group of
phosphodiesterase E (PDE) (14$) (Fig. 1.9). There are at least seven known
distinct mammalian PDE families. Each one differs from each other in
HOOC
Figure 1.8 : Schematic representation of a soluble guanylate cyclase &
heterodimer.
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biochemical and physical properties, responses to specific effectors, inhibitors
and regulatory control mechanisms (14$). Type V PDE has been isolated from a
number of tissues including human platelets (149), trachea (150) and VSMC
(151) and is commonly referred to as cGMP-specffic PDE. PDE V is
characterized by selectively hydrolyzing only cGMP, independently of
Ca2/ca1modulln. Inhibitors of PDE V such as A02 131-1 have vasodilating and
anti-aggregating properties, which may protect the vascular wail against
arteriosclerotic changes (149).
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j1.14.6 NO in si2nal transduction
The endotheium serves as the principal physiological source of NO in
blood vessels (152). As evidenced, NO contributes to the regulation of several
hormone-mediated responses (153,154,155). In addition to its vasodilating
effect, NO can also inhibit atherogenesis (130), thrombocyte aggregation (156)
and VSMC proliferation (148,152) and migration (157). There is also increasing
body of evidence suggesting that NO is opposed to the physiological and
pathophysiological effects (14,137) of growth factors and vasoactive peptides
such as EGF (14$), PDGF (15$) and bFGF (157). Tins is probably achieved by
inhibiting one or several of the signaling events induced by these factors
(130,152,157,159,160). According to several studies, mitogens such as ET-1
stimulate the synthesis of DNA and ceil proliferation by activating the
phosphorylation cascade of MAPK (28,161,162,163). The potential mechanism
that could modulate VSMC proliferation is the release of NO by the
endothelium either via a cGMP-dependent (137,14$) or a cGMP-independent
mechanisms (164,165,166,169). In cardiomyocytes, ET-1 -induced protein
synthesis (170,171) has also been shown to be inhibited by NO (167).
Furthermore, NO was recently found to suppress the AII-induced activation of
three major MAPKs, ERK1/2, p38mapk and JNK (16$) as weil as Pyk2 (155) in
cardiac fibroblasts. However, it is flot known whether NO similar to ils effect on
growth factor and MI-induced responses can also modulate signaling events
triggered by ET-1 receptor activation in VSMC. In smooth muscle-derived A7r5
jceils, NO has been shown to regulate PDGF-induced activation of PKB (154).
These data implicate the PKB signaling cascade as an important mitogenic
pathway that is subjected to modulation by NO in VSMC (154). However, the
role of NO/cGMP in modulating PKB signaling pathway in response to ET-1
has not yet been investigated in any ceil type.
1.15 Obiectives ofthe present study
As described above, ROS play an essential role in propagating the signais
ofseveral growth factors such as EGF, PDGF and Ail. The contribution ofROS
in ET-1-induced MAPK activation remain controversial and there are no reports
documenting the activation of PKB as well as Pyk2 by ET-1 in VSMC.
Therefore, we have undertaken tins study to elucidate a role of ROS on key
components of ET-1 signaiing system as well as protein synthesis in V$MC, and
have examined whether ROS generation contributes towards thefr response.
Furthermore, since NO is an important modulator of intracellular signaling
system by many growth factors such as PDGF and EGF in VSMC as well as MI
in cardiac fibroblasts. We have also investigated a possible role of NO on ET-1-
sensitive signaling systems in VSMC. We first elucidated the role of NO on key
components of ET-1 signaling systems ERK1/2, PKB and Pyk-2 as well as
protein synthesis in VSMC. We then used 8-Bromo-cGMP, a cycic GMP
analogue and ODQ, an inhibitor of sGC, to examine whether NO is acting
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through a cGMP-dependent mechanism. These studies have utilized standard
protocols of ceil biology such as ceil culture, SDS-PAGE, western bloting as
wefl as radioisotopes.
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Abstract
Reactive oxygen species (ROS) have been shown to mediate the effect of
several growth factors such as angiotensin II (MI), epidermal growth factor
(EGf) and platelet-derived growth factor (PDGf). Endothefin-1 (ET-1) is an
important growth factor for vascular smooth muscle ceils (VSMC) which is
beieved to contribute to the pathogenesis of vascular abnormalities such as
atherosclerosis, hypertension and cardiac hypertrophy. However, a possible roTe
of ROS generation in mediating the ET-1 response on ERK1/2 and PKB, key
components of growth promoting and proliferative signaling pathways, has flot
been examined in detail. Therefore, the aim of the present study was to
investigate the involvement of ROS in ET-1-mediated activation of ERKÎ/2 and
PKB as well as Pyk2 in A-10 VSMCs. Pyk2 is a non-receptor protein tyrosine
kinase and an upstream regulator of MAPK signaling. ET-1 stimulated the
phosphorylation of ERK1/2, PKB and Pyk2 in a dose and time-dependent
fashion with maximum response being eicited at 10 nM winch peaked at 5 min.
Treatment ofV$MC with ET-1 resulted in an increase in the generation ofROS
that could be btocked by diphenyleneiodonium (DPI), an inhibitor of NADPH
oxidase. furthermore, DPI pretreatment of ceils prior to stimulation with ET-1,
attenuated ET-1 enhanced phosphorylation of ERK1/2, PKB and Pyk2. N
acetylcysteine (NAC), another ROS scavenger, also exhibited a similar
response. Moreover, DPI also caused a decrease in the protein synthesis
stimulated by ET-1. These resuits demonstrate that ROS is a critical mediator of
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ET-1-induced signahng events linked to hypertrophic and growth promoting
pathways in VSMC.
Key words: ROS, ET-1, MAPK, ERK1/2, PKB, Pyk2, A-10 ceils.
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Introduction
Endothelin-1 (ET-1), a 21-amino acid peptide hormone, exhibits
vasoconstrictor (1) and mitogenic (2) properties. These effects of ET-1 are
elicited through the activation of 2 receptor subtypes, ETA and ETB, which
belong to a family of heptahelicai G-protein-coupled receptors (GPCRs) (3-5).
ET-1 receptor activation is coupled to multiple signaling pathways, such as
phospholipases C and D (6), Ca2 (7), mitogen-activated protein kinases
(MAPKs), including extracellular signal-reguiated kinases 1 and 2 (ERK1/2),
c-Jun-NH2-terminal kinase (JNK), and p3SMAPK (8-11) as well as
phosphatidylinositol 3-kinase (12). Extensive studies, carried out predominantiy
in cardiomyocytes (6, 8, 2$) and glomerular mesangial ceils (11, 12), have
implicated both receptor and non-receptor protein tyrosine kinases (PTKs) in
transducing ET-1 -evoked signaling responses (11, 15-18). Various PTKs
activated by ET-1 include c-Src (13-15), epidermal growth factor (EGF) (17)
and a Ca2tdependent PTK, Pyk2 (11, 17).
Recent experiments have indicated that reactive oxygen species (ROS)
play an essential role in propagating the signais of several growth factors,
peptide hormones and cytoldnes, such as piatelet-derived growth factor (19),
EGf (20), angiotensin II (AIl) (21), insulin (22), interleuldn-1 (23) and tumor
necrosis factor-Œ (24). Increased ROS generation has been linked to the
pathogenesis of several cardiovascular diseases, such as hypertension,
atherosclerosis, restenosis and congestive heart failure (29-31). ET-l lias also
‘fi
been shown to augment ROS production in various ceil types (25-27), and a role
of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in
the ET-1 -induced elevation of vascular ROS production has been suggested
recently (32).
Although it has been reported that ROS mediate ET-1 -stimtttated
activation of ERK1/2 and JNK (27), to the best of our knowledge, a detailed
investigation into the contribution of ROS in other ET-1 -evoked growth
promoting signaling pathways has not been carried out. Moreover, despite the
fact that ET-1-induced vascular smooth muscle celi (VSMC) proliferation (26,
33) and fibrogenesis (15) may contribute to vasculature remodeling leading to
vascular disease, flot much information is available on ET-1 -evoked signaling in
these ceils. Therefore, in the present studies, we have investigated the effect of
ET-1 on ERKÎ/2, protein kinase B (PKB) and Pyk2, key regulators of the
proliferative signaling pathway in A-10 VSMCs, and examined whether ROS
generation contributes to their activation.
44
Materials and Methods
Materials
ET-1 was purchased from Peninsula Laboratories (Belmont, CA, USA),
and N-acetyl-L-cysteine (NAC), diphenyleneiodonium (DPI) and bis-N
methylacridinium nitrate (lucigenin), from Sigma (St. Louis, MO, USA).
Monoclonal phospho-specffic-Tyr204-ERKY/2 antibody, polyclonal ERK1/2
antibody and horseradish peroxidase-conjugated goat anti-mouse
immunoglobulin were from Santa Cruz Biotecbnology Inc. (Santa Cruz, CA,
USA). Polyclonal phospho-specffic-Ser473-PKB and total PKB as well as
phospho-specfflc-Tyr402-Pyk2 and total Pyk2 antibodies were procured from
New England Biolabs (Beverly, MA, USA). The enhanced chemiluminescence
(ECL) detection system kit and L-(4,5-3H) leucine were from Amersham
Pharmacia Biotech (Baie d’Urfé, QC, Canada).
Methods
Cet! culture
VSMC derived from embryonic rat thoracic aorta A-10 ceils were
maintained in culture with DMEM containing 10% fetal bovine serum at 37°C in
a hurnidffled atmosphere of 5% C02, as described earlier (34). The ceils were
grown to $0-90% confluence in 60-mm plates and incubated in serum-free
DMEM 20 h prior to the treatments.
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Cet! tysis and Western btotting
Cefis incubated in the absence or presence of various agents were washed
twice with ice-cold PBS and lysed in 200 t1 of buffer (25 mlvi Tris-HC1, pH 7.5,
25 mM NaC1, 1 mM Na orthovanadate, 10 mM Na fluoride, 10 mM Na
pyrophosphate, 2 mM benzamidine, 2 mM ethylenebis(oxyethylenenitrolo)
tetraacetic acid, 2 mM ethylenediamine tetraacetic acid, I mM
phenyhnethylsulfonyl fluoride, 10 pg/ml aprotinin, 1% Triton X-100, 0.1%
sodium dodecyl sulfate (SDS) and 0.5 lg/ml leupeptin) on ice. The ceil lysates
were centrifuged at 12,000g for 10 min at 4°C. Protein concentrations were
measured by Bradford assay. Equal amounts of prote in were subjected to 10%
SDS-polyacrylamide gel (SDS-PAGE), transfened to PVDF membranes
(Mifiipore, MA, USA) and incubated with respective primary antibodies
(monoclonal phospho-specffic-Tyr204-ERK1 /2 antibody (1:2,000), polyclonal
phospho-speciflc-Ser473-PKB antibody (1:4,000), phospho-specffic-1yr402-Pyk2
antibody (1:1,000)). The antigen-antibody complex was detected by a
horseradish peroxidase-conjugated second antibody (1:4,000), and protein bands
were visualized by ECL. The intensity of specific bands was quantffied by NIH
Image software as described previously (35).
Measurement afROS generalion
ROS production was measured by the lucigenin method (21) with minor
modifications (36). Briefly, the ceils were preincubated in the absence or
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presence of 10 !IM DPI in DMEM for 30 mm, then treated with ET-1 (10 nM
for 5 mm). They were trypshuized, collected by centrifugation, and the peflet
was washed in modffied Krebs buffer containing NaC1 (130 mM), KCT (5 mM),
MgC12 (1 mM), CaC12 (1.5 mM), K2HPO4 (1 mM), and HEPES (20 mM), pH
7.4. Aller washing, the cefis were resuspended in Krebs buffer, and the ceil
concentration was adjusted to 1 x 1 in 900 d buffer. To measure ROS
production, the ceil suspension was transferred to plastic tubes and assessed in a
luminometer (LB 9507, Berthold, Wildbad, Germany). Measurernent was started
by an injection of 100 il lucigenin (linal concentration 5 x 10 M) at time zero.
Photon emission was counted every 5 min for up to 20 min. The emission in
relative light units was corrected for nonspecific luminescence in the absence of
ceils. Modified Krebs buffer was used as a control (blank). Solutions containing
DPI in the absence of ceils did flot display any significant interference in the
lucigenin assay.
Measurement of[3HJteucine incorporation
A-10 ceils were treated for 20 h with endothelin- 1 (10 nM; Belmont, CA,
USA). Protein synthesis was assessed by the addition of 2 .iCi!mL of
[3Hjleucine (ICN Biomedicals, Inc., Costa Mesa, CA, USA) for a period of 20 h.
To assess the role ofreactive oxygen species (ROS), ceils were pretreated for 30
min with DPI (5 .tM; Sigma, St-Louis, MO, USA), a specific inhibitor of
flavoprotein, NADH!NAD(P)H oxidase (32,37). Following the completion of
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the experimental protocol, A-10 ceils were washed twice with cold PBS, and 1
ml of cold 5% trichioroacetic acid was added for 30 min to precipitate protein.
The precipitates were subsequently washed twice with cold water and
resuspended in 500 d of 0.4 M NaOH. Aliquots were counted in a scintillation
counter.
$tatistics
$tatistical analysis was performed by one-way, repeated-measures analysis
of variance (ANOVA) followed by a Fisher post hoc test. AU data are reported
as means ± SE. The differences between means were considered significant at
P< 0.05.
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Resuits
Efftct ofET-1 on ERK1/2, PKB and Pyk2 phosphorytation in A-10 V$MCs
Our hiltial experiments were aimed at analyzing the effect of ET-1 on the
phosphorylation of 3 key elements of the signaling pathway, namely, ERK1/2,
PKB and Pyk2. Their activation was assessed by using phospho-specific
antibodies against each of these kinases. As shown in Figure 1, ET-1
concentration-dependently enhanced the phosphorylation of ERK1/2 (Fig. lA),
PKB (Fig. lB) and Pyk2 (Fig. 1C). In each case, maximum phosphorylation
occurred at ET-1 concentrations of 1-10 nM. Next, we analyzed the time
dependence ofthe ET-1 response at 10 nM. As seen in Figure 2, ET-1 treatment
of A-10 ceils rapidly increased the phosphorylation of ERK1/2 (Fig. 2A), PKB
(fig. 2B) and Pyk2 (Fig. 2C). A significant increment was detected within 1 min
of treatment and peaked at about 5 mm, then gradually declined to submaximal
levels at 30 to 60 min. No alteration in the total amount of ERK1/2, PKB or
Pyk2 was observed under these experimental conditions.
Effect ofDPI on ET-1-induced phosphorytation ofERK1/2, PKB and Pyk2 in
A-10 VSMCs
To investigate whether ROS generation was involved in ET-1-induced
activation of ERK1/2, PKB and Pyk2, we utffized DPI, a frequently-employed
hihibitor of the flavoprotein NADHINAD(P)H oxidase (32,37). As depicted in
Figure 3, DPI pretreatment concentration-dependently inhibited ET-1-induced
phosphorylation of ERK1/2 (fig. 3A), PKB (Fig. 3B) and Pyk2 (Fig. 3C).
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However, among the 3 kinases, Pyk2 appeared to be most sensitive to inhibition
by DPI, winch elicited a signilicant reduction in phosphorylation at 1 1iM (Fig.
3C). At tins DPI concentration, ERK1/2 phosphoiylation was flot signfficantly
affected (Fig. 3A), and PKB phosphorylation was suppressed only slightly (Fig.
3B), whereas 10 jiM DPI pretreatment was found to block ET-1-induced
phosphorylation of ail the kinases by about $0 % (Fig. 3).
Effecis ofET-1 and DPI on ROS generation in A-10 VSMCs
The resuits described above suggested that ROS generation by a DPI
inhibitable NADPH oxidase might contribute to ET-1-induced ERKÏ/2, PKB
and Pyk2 phosphorylation. Therefore, we evaluated the effect of ET-1 on ROS
generation in A-10 ceils by the lucigenin chemiluminescence method. As
fflustrated in Figure 4, stimulation with 10 nM ET-1 for 5 min evoked a
signi±icant increase of ROS production in A-10 ceils. However, their treatment
whh DPI prior to stimulation with ET-l almost completely blocked ET-1-
evoked ROS production. These resuits revealed that in A-10 ceils, ET-1 caused
an increase in ROS production winch was suppressed by DPI. DPI alone had no
significant effect on the basal production ofROS (data flot shown).
Effeci ofNAC on ET-1-induced ERK1/2, PKB and Pyk2 phosphorytation in
A-10 VSMCs
To further conllrm a role ofROS in ET-1-induced responses, we tested the
effect of NAC, a thiol-containing agent, on ERK1I2, PKB and Pyk2
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phosphorylation by ET-l. VSMCs were preincubated with NAC for 6 h and then
stimulated with ET-1 for 5 min. As shown in Figure 5, NAC treatment
decreased ERK1/2, PKB and Pyk2 phosphorylation induced by ET-1. As with
DPI (Fig. 3), attenuation of Pyk2 phosphorylation by NAC was more potent
compared to ERK1/2 and PKB phosphorylation by ET-1.
Effect ofDPI on protein synthesis induced by ET-1 in A-10 VSMCs
Since increased protein synthesis is one of the physiological consequences
of ET-1 receptor activation, we evaluated whether ET-1-induced protein
synthesis in A- 10 VSMCs is also regulated by ROS generation. As presented in
Figure 6, treatment of A-10 ceils with ET-1 heightened [3Hlleucine
incorporation into protein. ET-1 caused more than a 3-fold increment ofprotein
synthesis, winch was almost completely attenuated in ceils pretreated with DPI.
However, DPI did flot significantly affect basal [3Hjleucine incorporation.
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Discussion
In the present studies, we have demonstrated that ET-1 stimulated
ERK1/2, PKB and Pyk2 phosphorylation in A-10 V$MCs. Mthough earlier
investigations in cardiomyocytes (6,8,28) and glomerular mesangial ceils
(11,12) have reported ET-1 -induced activation of ERK1 /2 (8-10) and Pyk2
(11,17), similar work in VSMC has not been conducted. Moreover, an effect of
ET-1 on PKB phosphorylation has not been examined previously. Thus, our data
represent a first demonstration of ET-1-induced ERKY/2, PKB and Pyk2
activation in VSMCs. These signaling components are believed to be arnong the
key players mediating the growth, proliferation, hypertrophy, migration and
survival responses of the ceils (38). Activation of ERK1/2 signaling pathways
has been suggested to be important for ET-1 -induced proliferation of VSMCs
(39) and myometrial ceils (14) as well as ceil cycle progression ofNIH 3T3 ceils
(40).
Pyk2 has been shown to serve as an upstream regulator of ERK1/2 and
PKB activation by Ail in VSMCs (41), but ET-1-induced ERKY/2
phosphorylation in kidney mesangial ceils (12) and neonatal cardiomyocytes
(17) appears to be Pyk2-independent. Thus, it is possible that Pyk2 regulates
ERK1/2 phosphorylation in a ligand-specific manner. The time-course of Pyk2
and ERK1/2 phosphorylation in A-10 V$MCs (Fig. 2) showed almost an
identical pattem, and did flot provide any evidence for a potential temporal
relationship between the 2 kinases. Thus, more detalled kinetic analysis wfth
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pharmacological and genetic tools wffl be required to test the role of Pyk2 in
mediating ET-1 -induced responses in V$MCs. ET-1 was recently demontrated
to exert an anti-apoptotic effect in cardiomyocytes (42), but its influence on
PKB activation was not investigated in these studies. Since PKB is believed to
exert an anti-apoptotic action through the phosphorylation of BAD and caspases
(38), it may be postulated that ET-I-induced activation of PKB contributes to
tins response.
Another important finding of the present work is that DPI, an inhibitor of
NADPH oxidase, blocked ET-1-evoked enhancement of ERK1/2, PKB and
Pyk2 phosphorylation. We further demonstrated that ET-1 caused an increase in
ROS generation, winch was bÏocked in ceils pretreated with DPI. These
observations are consistent with a role of ROS as a mediator of the ET-1
response in A-10 V$MCs. However, in some earlier studies, DPI pretreatment
was shown to speciflcally inhibit ET-1-induced JNK and p3$MAPK
phosphorylation without affecting ERK1/2 phosphorylation in VSMCs isolated
from the aduit rat aorta (27,39). These data argue against a role for ROS
generation in ET-1 -induced ERKI /2 phosphorylation in aduit rat VSMCs.
In contrast to studies in VSMCs, ROS involvement in ET-1-stimulated
ERK1/2 phosphorylation in cardiac fibroblasts has been suggested (43). In
addition, divergent effects of DPI on MI-induced ERK1/2 phosphorylation in
VSMCs have also been noted. For example, an inhibitory action of DPI on Ail-
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stimulated ERK1/2 phosphorylation was demonstrated by frank et al. (37),
whereas Viedt et al. (44) and Touyz et al. (45) failed to detect any influence of
DPI on ERK1/2 phosphorylation. The reasons for these conflicting data remain
unclear, but differences in the DPI dose used or the time of DPI pretreatment as
well as the cefi types or culture conditions might have contributed to these
varied responses. Our data on NAC, a free radical scavenger, winch almost
completely attenuated the effect of ET-1 on ERKÎ/2, PKB and Pyk2
phosphorylation provided additional support for the involvement of ROS
generation in mediating the action of ET-1 in A-10 V$MCs.
We have also demonstrated that ET-1 treatment stimulated the rate of
protein synthesis in VSMCs. Although ET-1 has been shown to enhance protein
synthesis (46) via the ERK1/2 signaling pathway (2$), no substantial work into
its effect on protein synthesis in V$MCs has been conducted. Moreover, a clear
role of ERK1/2 in the process in VSMCs has flot been established. However,
since DPI pretreatment blocks both ERK1/2 phosphorylation and protein
synthesis in A-10 VSMCs, an involvement of tins pathway in mediating tins
response may be hypothesized.
In conc1usion we have demonstrated that ET-1 -induced activation of DPI
sensitive NADPH oxidase contributed to ROS generation in A-10 V$MCs. RO$
generation was also involved in the enhanced phosphorylation and activation of
ERK1/2, PKB and Pyk2 as well as protein synthesis in A-10 VSMCs. From
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these data, we conclude that ROS plays a critical role in triggering ET-1 -induced
signaling pathways linked to growth-promoting responses.
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Figure ]egends
Figure 1. ET-1-induced dose-responses of ERK1/2, PKB and Pyk2
phosphorylation in A-10 VSMCs. Serum-starved quiescent A-10 ceils were
treated without or with the indicated ET-1 concentrations for 5 min. Ceil lysates
were immunoblotted by phospho-specffic-Tyr204-ERK1/2 antibodies (A),
phospho-specffic-Ser473-PKB antibodies (B) and phospho-specffic-Tyr402-Pyk2
antibodies (C), as shown in the middle panels of each section. Blots were also
analyzed for total ERK1/2, PKB and Pyk2 (bottom panels ofeach section). Top
panels represent average data quantffied by densitometric scanning of
immunoblots. Values are the means ± SE of at least 3 independent experiments
and are expressed as fold increase over basal phosphorylation. (A) *,D< 0.002 vs
control. (B) *< 0.02 vs control. (C) *< 0.006 vs control.
Figure 2. lime-course of ET-1-induced ERK1/2, PKB and Pyk2
phosphotylation in A-10 VSMCs. Serum-starved quiescent A-10 ceils were
treated without or with ET-l (10 nM) for the indicated time periods. Ceil
lysates were immunoblotted by phospho-specffic-Tyr204-ERK1/2 antibodies (A),
phospho-specffic-Ser473-PKB antibodies (B) and phospho-specffic-Tyr402-Pyk2
antibodies (C), as shown in the middle panels of each section. Blots were also
analyzed for total ERK1/2, PKB and Pyk2 (bottom panels ofeach section). Top
panels represent average data quantffied by densitometric scanning of
immunoblots. Values are the means ± SE of at least 3 independent experiments
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and are expressed as fold increase over basal phosphorylation. (A) *.,D< 0.007 vs
control. (B) *P< 0.03 vs control. (C) *< 0.02 vs control.
Figure 3. Dose-dependent effect of the NADPH oxidase inhibitor DPI on
ET-1-induced ERK1I2, PKB and Pyk2 phosphorylation in A-10 VSMCs.
Serum-starved quiescent A-10 ceils were pretreated without or with the
indicated DPI concentrations for 30 mm, followed by 10 nM of ET-1 for 5 min.
Ceil lysates were immunoblotted by phospho-specffic-Tyr204-ERKY /2 antibodies
(A), phospho-specffic-Ser473-PKB antibodies (B) and phospho-specffic-Tyr402-
Pyk2 antibodies (C), as shown in the middle panels of each section. Blots were
also analyzed for total ERK1/2, PKB and Pyk2 (bottom panels of each section).
Top panels represent average data quantffied by densitornetric scanning of
immunoblots. Values are the means ± SE of at least 3 independent experiments
and are expressed as percentage phosphrnylation where phosphorylation
observed with ET-1 aTone is defined as 100%. (A) *P< 0.0001 vs control, tP<
0.0001 vs ET-1. (B) *P< 0.0001 vs control, fP< 0.02 vs ET-1. (C) *P< 0.02 vs
control, fP< 0.04 vs ET-1.
Figure 4. Effect of DPI on EI-1-induced ROS generation in A-10 VSMCs.
Serum-starved quiescent A-10 celis were pretreated without or with DPI (10
iM) for 30 min before the addition of ET-1 (10 nM) for 5 min. The ceils were
then trypsinized and collected by centrifugation for the assessment of ROS
generation as described in Materials and Methods. Relative light unit
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measurements were compared 5 min afler the addition of lucigenin. Non-treated
ceils were considered as controls. Values are the means ± SE of 3 independent
experiments; *< 0.02 vs control, tP< 0.02 vs ET-1
Figure 5: Effect of the superoxide scavenger NAC on ET-1-induced
ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serum-starved
quiescent A-10 ceils were pretreated without or with NAC (20 mM) for 6 h,
followed by 10 nM of ET-1 for 5 min. Ceil lysates were imrnunoblotted by
phospho-specffic-Tyr204-ERK1 /2 antibodies (A), phospho-specffic-5er473-PKB
antibodies (B) and phospho-specific-Tyr402-Pyk2 antibodies (C), as shown in the
middle panels of each section. Blots were also analyzed for total ERK1/2, PKB
and Pyk2 (bottom panels of each section). Top panels represent average data
quantffied by densitometric scanning of immunoblots. Values are the means ±
SE of at least 3 independent experiments and are expressed as percentage
phosphorylation where phosphorylation observed with ET-1 alone is deflned as
100%. (A) *P< 0.0001 vs control, tP< 0.005 vs ET-1. (B) *P< 0.0001 vs
control, tP< 0.009 vs ET-l. (C) *< 0.000$ vs control, tP< 0.04 vs ET-1.
Figure 6: Effect of DPI on ET-1-induced [3lllJeucine incorporation into
proteins. Serum-starved quiescent A-10 ceils were pretreated with DPI (5 1iM)
for 30 min in the absence (control) or presence of ET-l (10 nM); then, the ceils
were labeled to equffibrium with [3H]leucine for 20 h as described in Materials
and Methods. Values are the means ± SE of 3 independent experiments and are
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expressed as a percentage of change in [3H]leucine incorporation over basal
values. *P< 0.0002 vs control, tP< 0.0002 vs ET-1.
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Abstract
Nitric oxide (NO) is an important free radical that has been shown to
contribute to the regulation of several hormone-mediated responses including
EGF, PDGF as well as endothelin-1 (ET-1) and exerts an anti-mitogenic and
anti-proliferative effect in vitro. ET-1 is a vasoactive peptide implicated in the
pathogenesis of vascular abnormalities such as hypertension and atherosclerosis.
However, the mechanism by winch NO antagonizes ET-1 effect remains
unknown. Therefore, the aim of tins study was to determine if NO generation
would modify ET-1 -induced signaling pathways involved in cellular growth and
proliferation in A-10 VSMC. NO effect has been evaluated by measuring
phosphorylation levels of ERK1I2, PKB and Pyk2 by immunoblot. Treatrnent of
A-10 celis with S-nitroso-N-acetylpenicfflamine (SNAP), a NO donor,
attenuated the ET-1-enhanced phosphoiylation of ERK1/2, PKB and Pyk2.
Since, NO mediates principally its effect through a cyclic GMP/soluble
guanylate cyclase pathway, we investigated the role of $-Br-cGMP, a non
metabolizable and ceil permeable analogue of cGMP, which exhibited a similar
effect as SNAP on ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation.
Furthermore, ODQ, an inhibitor of guanylate cyclase activity, reversed the
inbibitory effect of NO on ET-1-induced responses. SNAP also appeared to
decrease the protein synthesis induced by ET-1. Taken together, these data
demonstrate that NO attenuated ET-1-induced phosphorylation ofERKY/2, PKB
and Pyk2 and also antagonized the growth-promoting, proliferative as well as
hypertrophic effects of ET-1.
Key words: NO, ET-1, MAPKs, ERK1/2, PKB, Pyk2, A-10 ceils
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introduction
The endothelium is the major source of endothelin-1 (ET-1) production
(1,2). ET-1 is a 21-aminoacid peptide and is considered as a potent
vasoconstrictor (3). It also exhibits mitogenic activity in vascular smooth muscle
celis (VSMC) (4,5,6), suggesting a possible role for ET-1 in the pathogenesis of
many diseases, such as atherosclerosis (7), hypertension (2) and restenosis afier
angioplasty (9).
ET-1 exerts its effects through heteromeric G-protein-coupled receptor
(GPCR) that is liriked to multiple signaling pathways winch include
phospholipases C and D (10), Ca2 (11), mitogen-activated protein kinases
(MAPKs) including extraceflular signal-regulated kinases 1/2 (ERK1/2), c-Jun
NH2-terminal kinase (JNK) and p38mapk (12,13,14,15) and
phosphatidylinositol 3-kinase (PI-3K) (16). Most of the studies related to ET-1
signaling have been conducted in cardiomyocytes (10,12,17) and in glomerular
mesangial ceils (15,16). Activation of receptor and non-receptor protein tyrosine
kinases (PTKs) in transducing ET-1-induced signaling responses have been
demonstrated (15,18,19,20,21). PTKs activated by ET-1 include epidermal
growth factor (EGf) (21), c-Src (18,20,22) and a Ca2-dependent PTK, Pyk2
(15,20). 0f particular interest, ET-1 mediates Pyk2 activation winch contributes
to ERKY/2 (20) and JNK (21) signaling in cardiomyocytes and p38mapk (15) in
mesangial ceils.
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Nitric oxide (NO) is an important free radical that has been suggested to
contribute to the regulation of several hormone-mediated responses (22). NO
mediates relaxation principally through the stimulation of soluble guanylyl
cyclase, leading to enhanced production of intracellular cGMP, which in tum,
activates cGMP-dependent protein kinases (23). NO can also influence ceflular
events by a cGMP-independent mechanism (24,25) and is also able to react with
superoxide anion to form the reactive peroxynitrite radical (26), a potent oxidant
with the potential to disrupt protein structures by nitrating the protein tyrosine
residues (27). In addition to its vasodilating effect, NO has been suggested to
antagonize the physiological and pathophysiological effects of several growth
factors such as EGF (2$), angiotensin II (AIl) (29) as well as ET-1 (30). Tins is
probably achieved by inhibiting one or several of the tyrosine kinases implicated
in the signaling events induced by these factors. Extensive studies using Ail,
have shown that NO suppressed the activation of ERK1/2, p3$mapk and JNK
(31) as well as Pyk2 (29) in cardiac fibroblasts.
However, to our knowledge, a possible contribution of NO on ET-1-
induced intracellular transduction events has flot been investigated in V$MC.
Therefore, in the present studies, we have examined the effect of NO on ET-1-
stimulated phosphorylation of ERK1/2, PKB and Pyk2 winch are key mediators
of growth promoting, proliferative, migratory, survival and death responses. In
addition, we have examined whether NO is acting via a cGMP-dependent
mechanism in the A-10 VSMCs. Our study demonstrated that NO donor, S-
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nitroso-N-acetylpenidilamine (SNAP), attenuated ET-1-induced ERK1/2, PKB
and Pyk2 phosphorylation via cGMP dependent pathway. These resuits
demonstrate that NO may contribute to the anti-mitogenic and anti-proliferative
effects by antagonizing growth promoting and proliferative signaling events in
VSMC.
$1
Materials and Methods
Materials
ET-1 was purchased from Peninsula Laboratories (Belmont, CA, USA),
and S-nitroso-N-acetylpenicfflamine (SNAP), 8-Bromo-guanosine 3’, 5’ -cydic
monophosphate ($-Br-cGMP) and 1H- [1 ,2,4JOxadiazolo [4,3 -a]quinoxalin- 1 -one
(ODQ), from Calbiochem (San Diego, CA, USA). Monoclonal phospho
specffic-Tyr204-ERK1/2 antibody, polyclonal ERK1/2 antibody and horseradish
peroxidase-conjugated goat anti-mouse immunoglobulin were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The phospho-specffic-Ser473-PKB
and total PKB as well as phospho-specffic-Tyr402-Pyk2 and total Pyk2
antibodies were procured from New England Biolabs (Beverly, MA, USA). The
enhanced chemiluminescence (ECL) detection system kit and L-(4,5-3H) leucine
were from Amersham Pharmacia Biotech (Baie d’Urfé, QC, Canada).
Methods
CeIt culture
VSMC derived from embryonic rat thoracic aorta A-10 ceils were
maintained in culture with DMEM containing 10% fetal bovine serum at 37°C in
a humidifled atmosphere of 5% C02 as described earlier (32). The ceils were
grown to $0-90% confluence in 60-mm plates and incubated in serum-free
DMEM 20 h prior to the treatments.
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Ce!! lysis and Western blotting
Ceils incubated in the absence or presence of various agents were washed
twice with ice-cold PBS and lysed in 200 r1 of buffer (25 mlvi Tris-HCI, pH 7.5,
25 mlvi NaCI, 1 mM Na orthovanadate, 10 mM Na fluoride, 10 mM Na
pyrophosphate, 2 mM benzamidine, 2 mM ethylenebis(oxyethylenenitrolo)
tetraacetic acid, 2 mM ethylenediamine tetraacetic acid, 1 mM
phenylmethylsuffonyl fluoride, 10 j.ig/ml aprotinin, 1% Triton x-100, o. 1%
sodium dodecyl sulfate (SDS), and 0.5 p.glml leupeptin) on ice. The cd lysates
were centrifuged at 12,000g for 10 min at 4°C. Protein concentrations were
measured by Bradford assay. Equal amounts of protein were subjected to 10%
SDS-polyacrylamide gel (SDS-PAGE), transferred to PVDf membranes
(Miffipore, MA, USA) and incubated with respective primary antibodies
(monoclonal phospho-spedilic-Tyr204-ERK1/2 antibody (1:2,000), polyclonal
phospho-specffic-Ser473-PKB antibody (1:4,000), phospho-specffic-Tyr402-Pyk2
antibody (1:1,000)). The antigen-antibody complex was detected by a
horseradish peroxidase-conjugated second antibody (1:4000), and protein bands
were visuallzed by ECL. The intensity of specific bands was quantffied by NIH
Image software as described previously (33).
Measurement of[3HJteucine Incorporation
A-10 ceils were treated for 20 h with endothelin-1 (10 nM; Belmont, CA,
USA). Protein synthesis was assessed by the addition of 2 jiCilmL of
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[3Hjleucine (ICN Biomedicals, Inc., Costa Mesa, CA, USA) for a period of 20 h.
To assess the role of nitric oxide (NO), ceils were pretreated for 30 min with S
nitroso-N-acetylpenicfflamine (SNAP) (300 jiM; Calbiochem, San Diego, CA,
USA) winch spontaneously generates NO. Following the completion of the
experimental protocol, A-10 ceils were washed twice with cold PBS, and 1 ml
of cold 5% trichioroacetic acid was added for 30 min to precipitate protein. The
precipitates were subsequently washed twice with cold water and resuspended in
500 d of 0.4 M NaOH. Aliquots were counted in a scintillation counter.
Statistics
Statistical analysis was performed by one-way, repeated-measures analysis
of variance (ANOVA) followed by a fisher post hoc test. AU data are reported
as means ± SE. The differences between means were considered significant at
P< 0.05.
$4
Resuits
SNAP inhibited ET-1-induced phosphorytation of ERK1/2, PKB and Pyk2 in
A-10 VSMCs
In order to determine if the anti-mitogenic and anti-proliferative effects of
NO are mediated by its abffity to attenuate growth-promoting signaling pathway
in V$MC, we examined the effect of $-nitroso-N-acetylpenicfflamine ($NAP),
winch spontaneously generates NO, on ET-1-induced phosphorylation of
ERK1/2, PKB and Pyk2. As shown in Figure 1, pretreatment of A-10 VSMC
with SNAP for 15 min dose-dependently attenuated ET-1-induced
phosphorylation of ail the 3 protein kinases. Among the 3 kinases, PKB
appeared to be most sensitive to the inbibitory effect of SNAP and exbibited
almost complete attenuation in ET-1-stimulated phosphorylation at 10 iM (fig.
lB). In contrast, ET-1-enhanced phosphorylation of ERK1/2 and Pyk2 was
inhibited significantly only by 300 jiM SNAP.
8-Br-cGMP tu!? ibited ET-1-induced phosphorytation ofERK1/2, PKB in A-10
VSMCs
Since SNAP-induced production of NO would cause the elevation of
cGMP, we evaluated the possibffity that the effect of SNAP on ET-1-induced
responses was mediated by a mechanism involving cGMP. We tested tins
possibility by pretreating the ceils with $-Br-cGMP, a non-metabolizable and
ceil permeable analogue of cGMP. As shown in Figure 2, ERKY/2 and PKB
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phosphorylation induced by ET-1 was decreased in a dose-dependent manner
with a significant reduction observed at 10 j.iM.
ODQ reversed lite inhibitory effect of SNAP on ET-1-induced ERK1/2, PKB
and Pyk2 in A-10 VSMCs
Since NO stimulates cGMP production by activating a soluble form of
guanylate cyclase, we wished to determine the contribution of tins enzyme in
SNAP-induced attenuation of ET-1 response. To validate tins possibffity, we
used ODQ, a selective inhibitor of the soluble guanylate cyclase, winch prevents
the generation of cGMP from GTP. Ceils for these experiments, were
preincubated with ODQ for 15 mm, then with 300 jiM SNAP for 15 min and
finally stimulated with 10 nM ET-1 for 5 min. As shown in Figure 3,
pretreatment with 1 iM ODQ had no significant effect but 10 pM ODQ
completely reversed the inhibition induced by SNAP on ET-1 -stimulated
ERK1/2, PKB and Pyk2 phosphorylation (fig. 3).
SNAP inhibited ET-1-stimutated [3HJleucine incorporation mb proteins
Activation of ERK1/2, PKB and Pyk2 signaling has been implicated in
mediating the hypertrophic response of ET-1 (17), therefore, we next examined
whether there was correlation between the response of $NAP and ET-1 -induced
protein synthesis. As shown in Figure 4, ET-1 increased [3H]leucine
incorporation by about 150% as compared to control. However, pretreatment
with SNAP caused a significant decrease of ET-1 induced [3HJleucine
26
incorporation. SNAP alone did flot signfficantly affect the basal [3H]leucine
uptake.
$7
Discussion
Nitric oxide (NO), a gaseous biological molecule and a major vasodilator
released from the endothelial ceils, has been identilied to regulate cellular
functions. In addition to the relaxation of smooth muscle ceils, NO can also
inhibit atherogenesis, thrombocyte aggregation as well as ceil proliferation and
migration. NO donors have been found to attenuate EGf (2$), PDGF (34) and
angiotensin II (AIl) (35) stimulated proliferation of V$MC and cardiac
fibroblasts. It has been suggested that NO might exert these effects by
modifying the growth-promoting signaling events. The support for this notion is
provided from studies in which NO was shown to attenuate Ras/ERKI/2
signaling in response to EGF(2$) and Ail (31) as well as PKB in response to
PDGF (34). NO was also shown to attenuate MI-stimulated Pyk2
phosphorylation in cardiac fibroblasts (29). Despite the fact that a potential
cross-ta& between ET-1 and NO exists, and that NO is believed to counteract
the effects of ET-1, not much information on the abffity of NO to modify’ ET-1-
induced signaling in VSMC is avallable. Therefore, in the present studies, we
have investigated if NO generation would modiI’ ET-1 -induced signaling
pathways involved in cd growth and proilferation.
Ffrst, a time and dose-dependent phosphorylation of ERK1/2, PKB and
Pyk2 by ET-1 were established (data flot shown). Our data indicated that
addition of the NO donor, $NAP decreased the phosphorylation level of
ERK1/2, PKB and Pyk2 involved in ET-1 signaling pathway (fig. 1). These
8$
resuÏts are similar to previous studies in which ATI-induced phosphorylation of
ERK1 /2 and Pyk2 was biocked by SNAP (29,31). However, otir work represents
the flrst study demonstrating a role that NO antagonizes ET-1 -induced signaling
in VSMC. Pyk2 has also been implicated in MI and ET-l-induced MAPK
activation in cardiac fibroblasts and V$MC. Thus, it is possible that Pyk2 serves
as an upstream mediator ofET-1-signaling in A-10 VSMC.
We have aiso demonstrated a role of cGMP in mediating the attenuating
effect of NO on ET-1 signaling pathway by using $-Br-cGMP. The resuits
showed that $-Br-cGMP decreased ERK1/2 and PKB phosphorylation induced
by ET-1 (Fig. 2) and it thus mirnicked the inhibitory effect of SNAP. We ffirther
evaluated an involvement of soluble guanylate cyclase by using a specific
inhibitor, ODQ, and demonstrated that it couid reverse the inhibitory effect of
$NAP on ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation (Fig. 3). It has
been previously shown that ODQ can block SNAP-induced elevations in cGMP
levels in rat aortic VSMC (36), endothelial ceils (37) and cardiomyocytes (3$).
finally, we also provide evidence showing that ET-1-stimulated protein
synthesis, a haDrnark of hypertrophic response is also attenuated by NO donor,
SNAP (Fig. 4).
Taken together, we demonstrate that NO inhibits the ET-1 -stimuiated
increase of ERK1/2, PKB and Pyk2 activation in A-10 VSMC. Since ERK1/2,
PKB and Pyk2 plays a crucial foie by mediating VSMC growth and
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hypertrophy, it may be suggested that the abffity of NO to attenuate these
pathways may serve as a potential mechanism by which NO counteracts the
biological responses of ET-1.
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Figure Iegends
Figure 1. Dose-dependent effect of the NO donor, SNAP on ET-1-induced
ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serurn-starved
quiescent A-10 ceils were pretreated without or with the indicated SNAP
concentrations for 15 min followed by 10 nM of ET-1 for 5 min. Ceil lysates
were immunoblofted by phospho-specffic-Tyr204-ERK1/2 antibodies (A),
phospho-speci±ic-Ser473-PKB antibodies (B) and phospho-specific-Tyr402-Pyk2
antibodies (C), as shown in the middle panels of each section. Blots were also
analyzed for total ERK1/2, PKB and Pyk2 (bottom panels of each section). Top
panels represent average data quantified by densitometric scaiming of
immunoblots. Values are the means ± SE of at least 3 independent experiments
and are expressed as percentage phosphorylation where phosphorylation
observed with ET-1 alone is defined as 100%. (A) *P< 0.0001 vs control, P<
0.0001 vs ET-1. (B) *P< 0.0001 vs control, tP< 0.0001 vs ET-1. (C) *F< 0.002
vs control, tF< 0.0003 vs ET-l.
Figure 2. Effect of a stable analogue of cGMP, $-Br-cGMP on ET-1-
induced ERK1/2 and PKB phosphorylation in A-10 VSMCs. Serum-starved
quiescent A-10 ceils were pretreated without or with the indicated 8-Br-cGMP
concentrations for 15 min followed by 10 nM of ET-1 for 5 min. Cd lysates
were immunoblotted by phospho-specffic-Tyr204-ERKY/2 antibodies (A) and
phospho-specffic-Ser473-PKB antibodies (B), as shown in the middle panels of
each section. Blots were also analyzed for total ERK1/2 and PKB (bottom
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panels of each section). Top panels represent average data quantffied by
densitometric scarming of inimunoblots. Values are the means ± SE of at least 3
independent experiments and are expressed as percentage phosphorylation
where phosphorylation observed with ET-1 alone is defined as 100%. (A)
*< 0.003 vs control, tP< 0.005 vs ET-1. (B) *F< 0.0001 vs control, tP<
0.0003 vs ET-1.
Figure 3. Effect of the inhibitor of the soluble guanylate cyclase, ODQ on
ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs.
$erum-starved quiescent A-10 ceils were pretreated without or with the
indicated ODQ concentrations for 15 min before addition of 300 iM SNAP for
15 min followed by 10 nM of ET-1 for 5 min. Ceil lysates were immunoblotted
by phospho-specfflc-Tyr204-ERK1/2 antibodies (A), phospho-specffic-$er473-
PKB antibodies (B) and phospho-specffic-Tyr402-Pyk2 antibodies (C), as shown
in the middle panels of each section. Blots were also analyzed for total ERK1/2,
PKB and Pyk2 (bottom panels of each section). Top panels represent average
data quantffied by densitometric scanning of immunoblots. Values are the means
± SE of at least 3 independent experiments and are expressed as percentage
phosphorylation where phosphorylation observed with ET-1 alone is defined as
100%. (A) *< 0.0002 vs control, tP< 0.007 vs ET-1, P< 0.002 vs SNAP +
ET-1. (B) *P< 0.0002 vs control, tP< 0.0006 vs ET-1, 1 P< 0.003 vs $NAP +
ET-1. (C) *P< 0.0005 vs control, tP< 0.002 vs ET-1, P< 0.02 vs SNAP +
ET-1.
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Figure 4. Effect of SNAP on ET-1-induced (3HJ]eucine incorporation into
proteins. Serum-starved quiescent A-10 ceils were pretreated with SNAP (300
iM) for 30 min in absence (control) or in presence of ET-1 (10 nM), then the
ceils were labeled to equilibrium with [3HJleucine for 20 h as described in
Materials and Methods. Values are the means ± SE of 3 independent
experiments and are expressed as percentage of change in [3HJleucine
incorporated over the basal values. 0< 0.04 vs control, tP< 0.02 vs SNAP and
SNAP+ET-1.
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Endothelin-1 (ET-1) is the predominant isoform of the endothelin peptide
family and is synthetized mainly in the vascular endotheium and smooth muscle
ceils. Binding of ET-1 to ET-A receptors on vascular smooth muscle ceils
(VSMC) causes vasoconstriction and stimulates ceil growth and proliferation.
ET-l has been implicated in the pathogenesis of arterial hypertension, renal
disorders and cardiovascular diseases. Based on recent experimental data.,
treatment with newly available ET-1 antagonists is likely to inhibit ET-l -
induced funtional and structural alterations in the vasculature. However, a better
knowledge of ET-1 signaling transduction pathways would be important for
devising specific therapeutic agents directed against critical components of
signaling systems implicated in vascular remodeling.
ET-1 elicits its effects tbrough the stimulation of G-protein-coupled
receptors (GPCR) which Ïead to the recruitment of two distinct signaling
pathways: protein kinases of the Raf family and lipid kinases of the
phosphatidylinositol 3-kinase (PI-3K) family. Both pathways are shown to be
recruited by Ras, a smail G-protein, which is activated by ET-l (7,41,59). Rafis
the first member of the mitogen-activated protein kinase cascades (MAPK).
Several reports have demonstrated that ET-l activates MÀPK including
extracellular signal-regulated kinases 1/2 (ERK1 /2), c-Jun-NH2-terminal kinase
(JNK) and p3$mapk (56,163,172,173) as well as PI-3K (59) in many ceil types.
Several targets of PI-3K have been identffied, however, most widely studied
target is protein kinase B (PKB). Recently, ET-l lias been shown to slightly
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increase PKB phosphorylation in cardiomyocytes ($0). Moreover, various
receptor and non-receptor protein tyrosine kinases (PTKs) have been implicated
in transducing ET-1 -evoked signaling responses including c-Src, epidermal
growth factor (EGf) receptor and a Ca2-dependent PTK, Pyk2. Extensive
studies have been carried out predominantly in cardiomyocytes (7,172,174) and
gÏomerular mesarigial ceils (56,59) and have suggested a role for Pyk2 in ET-1-
induced activation of JNK (47) and p3 $mapk (56) signaling pathways. However,
the involvement of Pyk2 in ERKI/2 signaling pathway appeared to be less
predominant than for EGf receptor transactivation (60). We therefore
investigated the effect of ET-1 on ERKI/2, PKB and Pyk2 signaling winch are
believed to be key players in mediating growth-promoting, proliferative,
migratory, survival and death responses in the celi. In the present study, ET-1
showed an increase in ERK1/2 phosphorylation in A-10 VSMCs winch is
consistent with other studies done in VSMC (46,4$). However, these studies are
the first to report an activation ofPKB and Pyk2 by ET-1 in VSMCs.
A-10 VSMCs were grown uiti1 they become confluent, then were starved
in a medium without serum prior to the treatments. $erum-deprivation makes the
ceil quiescent and brings them to the stationary phase. Tins serum-deprivation
doesn’t change A-10 VSMCs morphology and they remain healthy without any
sign of apoptosis. Moreover, the quantification of proteins following each
experiment indicated the survival of the ceils. Serum contains many growth
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factors which activates several signaling moiecules, its presence would have
distorted the resuits by raising the basal phosphorylation levels ofproteins.
Several studies have indicated that reactive oxygen species (RO$) play an
essential role in propagating the signais of many growth factors, peptide
hormones and cytokines such as EGF (175), angiotensin II (MI) (176) and
tumor necrosis factor-Œ (TNF-Œ) (177). Increased ROS generation have been
associated with a variety of cardiovascular pathologies including hypertension
and atherosclerosis. ET-1 has been shown to increase ROS production in various
ccli types (30,125,128). Mso, NADPH oxidase lias been suggested to play a role
in the increase of vascular ROS production by ET-1 in endotheial ceils (118), in
pulmonary smooth muscle ceils (119) and in DOCA-sait rats (120). In VSMC
and endotheial cells, NADHINADPH oxidases represent the most important
source of superoxide anions (112). ROS also function as intracellular
messengers to modulate the signaling pathway and thus, regulate the
transcriptional activity in the ceil (125).
Conflicting resuits have been obtained on the role of ROS in mediating
ET-1-induced signaling. Fei et al. (12$) demonstrated that JNK activation but
flot ERK1/2 activation by ET-l was signfficantly inhibited by antioxidants in rat
smootli muscle ceils. Similarly, Kyaw et al. (30) showed that ET-1 induces JNK
and p3$mapk activation but flot ERKI/2 through ROS generation in VSMC. In
contrast, a recent study demonstrated that ROS plays a role in ET-1 -induced
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activation of ERK1/2 pathway as well as JNK and p38mapk in cardiac
fibroblasts (127). Thus, the contribution of ROS in ET-1-induced ERK1/2
activation is controversial and rernahis to be clarffled in VSMC. In addition, a
role ofROS to regulate PKB and Pyk2 signaling by ET-1 in VSMC has flot been
investigated.
Our resuits provided the flrst evidence that ROS mediates ERK1/2, PKB
and Pyk2 signaling induced by ET-1 via NADPH oxidase activation. In tins first
part of the study, we examined the effect of DPI, a potent inhibitor of flavonoid
contaiiiing enzymes, such as NADPH oxidase. Experiments with the
chemiluminescence reagent, lucigenin showed that stimulation with ET-1
induced generation of RO$ in A-10 VSMC, while treatment with DPI caused a
decrease of ROS generation in these ceils (Fig. 4, article 1). Furthermore, DPI
also inhibited ET-1 stimulation of ERKI/2, PKB and Pyk2 in A-10 VSMC,
which suggests the involvement of NADPH oxidase for ROS formation (Fig. 3,
article 1). To further confirm the role ofROS in A-10 VSMCs, N-acetylcysteine
(NAC), a superoxide scavenger, was also used in these experiments and showed
a decrease in ERK1/2, PKB and Pyk2 phosphorylation induced by ET-1 (Fig. 5,
article 1). In the present study, we found that NAC and DPI inhibited the
activation ofERK1/2 induced by ET-1 which is consisting with previous data on
cardiac fibrobÏasts (127). furthermore, we also showed that DPI could inhibit
ET-1 -induced protein synthesis of VSMCs. Increased protein synthesis and
accumulation of proteins are the essential component of the hypertrophie
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response observed with ET-1. Overali, our data reveal that ROS generation via
ftavonoid oxidases mediates ET-1 -induced key components of the signaling
pathway and it suggests that antioxidants can serve as attenuator of ET-1 action.
Nitric oxide (NO) is another important free radical that has been shown
to contribute to the regulation of several horrnone-mediated responses. NO has
been found to attenuate EGf (14$), PDGF (154) and angiotensin II (MI) (17$)
stimulated proliferation of VSMC and cardiac fibroblasts. It has been suggested
that NO might exert these effects by modifying the growth-promoting signaling
events. The support for this notion is provided from studies in winch NO was
shown to attenuate ras/ERK1/2 signaling in response to EGF(14$) and MI (16$)
as wefl as PKB in response to PDGf (154). NO was also shown to attenuate
MI-stimulated Pyk2 phosphorylation in cardiac fibroblasts (155). Despite the
fact that a potential cross-talk between ET-1 and NO exists, and NO is beheved
to counteract the effects of ET-1, flot much information on the abffity of NO to
modiÏy ET-1-induced signaling in V$MC is available. Therefore, in the present
studies, we have investigated if NO generation would modify ET-1 -induced
signaling pathways involved in cefi growth and proliferation.
Our data indicated that addition of the NO donor, SNAP decreased the
phosphorylation level of ERK1/2, PKB and Pyk2 invoÏved in ET-1 signaling
pathway. These resuits are similar to previous studies in winch AII-induced
phosphoiylation of ERK1/2 and Pyk2 was blocked by SNAP. However, our
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work represents the first study demonstrating that NO antagonizes ET-1 -induced
signaling in VSMC. Pyk2 has also been implicated in MI and ET-1-induced
MAPK activation in cardiac fibroblasts and VSMC. Thus, it is possible that
Pyk2 serves as an upstream mediator of MAPK cascade induced by ET-1 in A-
10 VSMC.
We have also demonstrated a role of cGMP in mediating the attenuating
effect of NO on ET-1 signaling pathway by using 8-Br-cGMP. The resuits
showed that $-Br-cGMP decreased ERK1/2 and PKB phosphorylation induced
by ET-1 (Fig. 2, article 2) and it thus mimicked the inhibitory effect of SNAP.
We further evaluated an involvement of soluble guanylate cyclase by using a
speci±ic inhibitor, ODQ, and demonstrated that it could reverse the inhibitory
effect of SNAP on ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation. It
has been previously shown that ODQ can block SNAP-induced elevation in
cGMP levels in rat aortic VSMC (166), endothelial ceils (179) and
cardiomyocytes (180). Finally, we also provide evidence showing that ET-1-
stimulated protein synthesis, a hallmark of hypertrophie response, is also
attenuated by NO donor, SNAP.
Taken together, we demonstrate that NO inhibits the ET-1 -stimulated
increase in the phosphorylation state ofERK1/2, PKB and Pyk2 in A-10 VSMC.
Since ERKI/2, PKB and Pyk2 plays a crucial role by mediating VSMC growth
and hypertrophy, it may be suggested that the ability of NO to attenuate these
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pathways may serve as a potential mechanism by which NO counteracts the
biological responses of ET-1.
CHAPTER 5
CONCLUSION
115
The resuits presented here demonstrate for the first time the involvement
of ROS in mediating ET-1 signaling components: ERKÏ /2, PKB and Pyk2 in
VSMC, winch were inhibited by antioxidants such as NAC and DPI. A role for
NADPH oxidase has been suggested in ET-1-enhanced ROS production.
Furthermore, ROS also contribute to increase protein synthesis induced by ET-1
in these ceils. Given the fact that NO has opposite effects to ET-1, studies were
expanded and demontrated a novel role for NO in regulating ERK1/2, PKB and
Pyk2 activation induced by ET-1 in a cGMP-dependent mechanism. We
reported that NO can also decrease ET-1-induced responses at the level of
protein synthesis.
Thus, the findings of the present study may augment the significant role of
antioxidants in ROS-mediated ET-1-induced signal transduction pathway and
suggest a clinical application of antioxidants in the pathogenesis of vascular
diseases. Moreover, the inhibitory effect of NO on the specific protein kinases as
weli as protein synthesis may offer a partial explanation for the antagonistic
effects of NO on ET-1 action in VSMC, winch contribute to the anti-mitogenic
and anti-proliferative effects (Fig. 5.10). NO could be of benefit in regulating
vascular remodeling of varïous diseases. However, NO is able to interfere with
diverse signaling pathways in various ceil types and it is suggested that a single
site of action probably is not enough to explain ail of the effects of tins
substance.
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signaling pathway.
CHAPTER 6
REFERENCES
11$
L Yanagisawa M, Kurihara H, Kimura S et al. A nove! potent vasoconstrictor
peptide produced by vascular endothelial ceils. Nature 332: 411-415, 1998.
2. Bobilc A, Grooms A, Mifiar JA, Mitcheli A and Grinpukel S. Growth factor
activity of endothelin on vascular smooth muscle. Am J Physiol 25$: C40$-
15, 1990.
3. Rabelink TJ, Kaasjager KA, Boer P, $troes EG, Braam B and Koomans HA.
Effects of endothelin-1 on renal fiinction in humans: implications for
physiology and pathophysiology. Kidney Int 46: 376-81, 1994.
4. Schiffiin EL. Endothelin: potential role in hypertension and vascular
hypertrophy. Hypertension 25: 1135-43, 1995.
5. Haynes WG and Webb DJ. Endothelin as a regulator of cardiovascular
fiinction in health and disease. JHypertens 16: 1081-1098, 199$.
6. Kedzierski RIVI and Yanagisawa M. Endothelin system: the double-edged
sword in health and disease. Annu Rev Pharmacot Toxicot 41: 851-76, 2001.
7. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J
Mol Ccii Cardiol 35: 87 1-886, 2003.
8. Goraca A. New views on the role of endothelin. Endocrine regulations 36:
161-167, 2002.
9. Simonson MS and Dunn MJ. Endothelin: pathways of transmembrane
signaling. Hypertension 15: I-5-12, 1990.
10. Emori T, Hirata Y, Ohta K, Kanno K, Eguchi S, 1mai T et al. Cellular
mechanisms of endothelin-1 release by angiotensin and vasopressin.
Hypertension 18: 165-170, 1991.
119
11. Gray GA. Generation of endothelin. In: Gray GA, Webb DJ (editors):
Molecular biology and pharmacology of the endothelins. Austin: RG
Landes. pp. 13-32, 1995.
12. Webb DJ, Monge JC, Rabelink TJ and Yanagisawa M. Endothelin: new
discoveries and rapid progress in the dlinic. Trends Pharmacol Sci 19: 5-2,
199$.
13. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D et al. ECE-1
membrane bound metalloprotease that catalyzes the proteolytic activation of
big endothelin-1. CeÏÏ 78: 473-485, 1994.
14. Monso D and Radomski MW. The nitric oxide-endothelin-1 connection.
Heart Failure Rev 8: 107-1 15, 2003.
15. Rubanyi GM and Polokoif MA. Endothelins: molecular biology,
biochemistry, pharmacology, physiology and pathology. Pharmacot Rev 46:
325-415, 1994.
16. Gulati A, Kumar A and Shahani BT. Cardiovascular effects of centrally
administred endothelin-1 and its relationship to changes in cerebral blood
flow. Life Sci 58: 437-45, 1996.
17. Evans RG, Bergstrom G, Cotterifi E and Anderson WP. Renal
haemodynamic effects of endothelin- 1 and the ETA/ETB antagonist TAK
044 in anaesthetized rabbits. J Hypertens 16: 1897-905, 199$.
1$. Adamicza A, Petak f, Asztalos T and Hantos Z. Effects of endothelin-1 on
airway and parenchymal mechanics in guinea pigs. Fur J Respir 13: 767-74,
1999.
120
19. Hocher B, Schwarz A, fagan KA, Thone-Reineke C, E1-Hag K et aï.
Pulmonary fibrosis and chronic lung inflammation in endothelin- I
transgenic mice. Am JRespir CeÏl Mol Biol 23: 19-26, 2000.
20. Kuwald T, Kurihara H, Cao WH, Kurihara Y, Unekawa M et al.
Physiological role of brain endothelin in the central autonomic control: from
neuron to knock out mouse. Prog Neurobiol 51: 549-79, 1997.
21. MacCarthy PA, Grocott-Mason R, Prendergast BD and Shah AM.
Contrasting inotropic effects of endogenous endothelin in the normal and
failing human heart: studies with an intracoronary ET(A) receptor
antagonist. Circulation 101: 142-147, 2000.
22. Endoh M, Fujita S, Yang HT, TaÏukder MA, Maruya J and Norota I.
Endothelin: receptor subtypes, signal transduction, regulation of Ca2
transients, and contractifity in rabbit ventricular myocardium. Lfe Sci 62:
1485-9, 199$.
23. Sugden PH. Signalling pathways in cardiac myocyte hypertrophy. Ann lied
33: 611-22, 2001.
24. Miyauchi T and Masaki T. Pathophysiology of endothelin in the
cardiovascular system. A nnu Rev Physiol 61: 391-415, 1999.
25. fujitani Y, Ninomiya H, Okada T, Urada Y and Masaki T. Suppression of
endothelin-1-induced mitogenic responses of human aortic smooth muscle
ceils by interleukin-1 beta. J Clin Invest 95: 2472-82, 1995.
26. MacNulty EE, Plevin R and Wakelam Mi. Stimulation of the hydrolysis of
phosphatidylinositol-4,5-bisphosphate and phosphatidylcholine by
121
endothelin, a complete mitogen for Rat-1 fibroblasts. Biochem J 272: 761-
66, 1990.
27. Ruetten H and Thiemermann C. Endothehn-1 stimulates the biosynthesis of
tumor necrosis factor in macrophages: ET receptors, signal transduction and
inhibition by dexamethasone. JPhysiol Pharmacol 48 : 675-88, 1997.
2$. Cheng CM, Hong HJ, Liu JC and Shih NL. Crucial of extracellular signal
regulated kinase pathway in reactive oxygen species-mediated endothelin- I
gene expression induced by endothelin-1 in rat cardiac fibroblasts. Mol
Pharmacol 63: 1002-11, 2003.
29. Wu-Wong JR, Chiou WJ and Wang J. Extracellular signal-regulated kinases
are involved in the antiapoptotic effect of endothelin- 1. J PharmacoÏ Exp
Ther 293: 5 14-521, 2000.
30. Kyaw M, Yoshizumi M, Tsuchiya K et al. Mtioxidants inhibit endothefin- 1
(1-31)-induced proliferation of vascular smooth muscle ceils via the
inhibition of mitogen-activated protein (MAP) kinase and activator protein- I
(AP-1). Biochem PharmacoÏ 64: 1521-31, 2002.
31. Sorokin A, foschi M and Dunn MJ. Endothelin signafling and regulation of
protein kinases in glornerular mesangial ceils. Clin Sel 103: 132S-136S,
2002.
32. Arai H, lori S, Aramon I, Okhubo H and Nakanishi S. Cloning and
expression of a cDNA encoding an endothelin receptor. Nature 348: 73 0-32,
1990.
122
33. Pierce KL, Premont RT and Le&owitz RI. Seven-transmembrane receptors.
Nat Rev Mol CelI Biol 3: 639-65 0, 2002.
34. Ruffolo R. Endothelin receptors from the gene to the human. Boca Raton,
fL: CRC Press, 1995.
35. Gellai M, fletcher T, Pullen M and Nambi P. Evidence for the existence of
endothelin-B receptor subtypes and their physiological roles in the rat. Am J
Physiol 27: R254-R261, 1996.
36. Gutkind JS. Ceil growth control by G-protein-coupled receptors: from signal
transduction to signal integration. Oncogene 17: 133 1-1342, 1998.
37. Rhee 5G. Regulation of phosphoinosïtide-specific phospholipase C. Annu
RevBiochem 70: 281-312, 2001.
3$. Fukami K. Structure, regulation, and ffinction of phospholipase C enzymes.
JBiochem 131: 293-9, 2002.
39. Newton AC. Protein kinase C: structural and spatial regulation by
phosphorylation, cofactors, and macromolecular interactions. Chem Rev 101:
2353-64, 2001.
40. Robin P, Boulven I, Desmyter C, Harbon S and Leiber D. ET-1 stimulates
ERK signaling pathway tbrough sequential activation of PKC and Src in rat
myometrial ceils. Am JFhysiol Ccli Physiol 283: C251-60, 2002.
41. Takai Y, Sasaki T and Matozaki T. Small GTP-binding proteins. Physiol Rev
81: 153-20$, 2001.
42. Seger R and Krebs EG. The MAPK signaling cascade. FA$E3 J 9: 726-73 5,
1995.
123
43. Su B and Karin M. Mitogen-activated protein kinase cascades and regulation
of gene expression. Curr Opin Immunot 3: 402-11, 1996.
44. Frodin M and Gammeltoft S. Role and regulation of 90 kDa ribosomal $6
kinase (RSK) in signal transduction. Mol Cet! Endocrin 151: 65-77, 1999.
45. Yue TL, Gu JL, Wang C, Reith AD et al. ExtracelluÏar signal-regulated
kinase plays an essential role in hypertrophic agonists, endothelin-1 and
phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 275:
37895-901, 2000.
46. Brehm BR, Klaussner M and Wolf SC. Chronic elevated endothelin- 1
concentrations regulate mitogen-activated protein kinases ERK1/2 in
vascular smooth muscle ceils. Clin Sci 48: 1375-140S, 2002.
47. Kodama H, Fukuda K, Takahashi E et al. Selective involvement of
p13 OCas/Crk’Pyk2/c-Src in ET-1 -induced JNK activation. Hypertension 41:
1372-9, 2003.
48. Chevalier D, Thorin E and Men BG. Simultaneous measurement of ERK.
p3 $ and ]NK MAPK cascades in vascular smooth muscle ceils. J Pharmacol
Toxicol Methods 44: 429-39, 2000.
49. Araki S, Haneda M, Togawa M and Kikkawa R. Endothelin-1 activates e
Jun-NH2 terminal kinase in mesangial ceils. Kidney Jnt 51: 631-9, 1997.
50. Clerk A, Pham FH, Fufler SJ, Sahai E and Aktories K. Regulation of
mitogen-activated protein kinases in cardiac myocytes through the small G
protein, Rac- 1. Mol Ce!! Bio! 21: 1173-$4, 2001.
124
51. Yee HF, Melton AC and Tran BN. RhoAJRho-associated kinase mediates
fibroblast. Biochem Biophys Res Commun 9: 1340-5, 2001.
52. Lewis TS, Shapiro P5 and Ahn NG. Signal transduction through MAP
kinase cascades. Adv Cancer Res 74: 49-139, 1998.
53. Chiloeches A, Paterson Uf, Marais RM, Clerk A, Marshall CJ and Sugden
PH. ReguÏation of Ras.GTP loading and Ras-Raf association in neonatal rat
ventricular myocytes by G protein-coupled receptor agonists and phorbol
ester. Activation of the extracellular signal-regulated kinase cascade by
phorbol ester is mediated by Ras. JBiol Chem 274: 19762-70, 1999.
54. Lev S, Moreno H, Martinez R, Canoil P, Peles E, Musacchio JM, Plowman
GD, Rudy B and Schiessinger J. Protein tyrosine kinase Pyk2 involved in
Ca2-induced regulation of ion channel and MAP kinase functions. Nature
376: 737-745, 1995.
55. Cazaubon S, Chaverot N, Romero TA. Girault JA, Adamson P, Strosberg AD
and Couraud P0: Growth factor activity of endothelin-1 in primary
astrocytes mediated by adhesion-dependent and —independent pathways. J
Neurosci 17: 6203-6212, 1997.
56. Sorokin A, Kozlowski P, Graves L and Philip A: Protein-tyrosine kinase
Pyk2 mediates endothelin-induced p38MAPK activation in glomerular
mesangial cefis. JBioÏ Chem 276: 21521-21528, 2001.
57. Sabri A, Govindarajan G, Griflin TM, Byron KL, Samarel AM and Lucchesi
PA: Calcium and protein kinase C depedent activation of the tyrosine kinase
125
Pyk2 by angiotensin II in vascular smooth muscle. Cire Res $3: $41-$51,
199$.
58. Dikic 1, Tokiwa G, Lev S, Courtneidge SA and Schiessinger J: A role for
PYK2 and Src in linking G-protein-coupled receptors with MAP kinase
activation. Nature 383: 547-550, 1996.
59. foschi M, Chari S, Dunn Mi and Sorokin A: Biphasic activation of p2 iras
by endothelin-1 sequentially activates the ERX cascade and
phosphatidylinositol 3-kinase. EMBOJ 16: 6439-6451, 1997.
60. Kodama R, fukuda K, Takahashi T and Sano M. Role of EGF receptor and
Pyk2 in endothelin- I -induced ERK activation in rat cardiomyocytes. J Mol
CeÏl Cardiol 34: 139-150, 2002.
61. Sakai R, Iwamatsu A, Hirano N, Ogawa S et al. A novel signaling molecule,
p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine
phosphorylation-dependent manner. EMBO J 13: 374$-3756, 1994.
62. Vuori K, Rirai H, Aizawa S and Ruoslahti E. Introduction of pl30cas
signaling complex formation upon integrin-mediated ceil adhesion: a role for
Src family kinases. Mol CeÏÏ BioÏ 16: 2606-2613, 1996.
63. Eguchi S, Numguchi K, Iwasaki H and Matsumoto T. Calcium-dependent
epidermal growth factor receptor transactivation mediates the angiotensin II
induced mitogen-activated protein kinase activation in vascular smooth
muscle ceils. JBiol Chem 273: $890-$896, 199$.
64. Yamaguchi M, Tanaka T, Wakai M, Kitanaka A, Kamano H, Kubota Y,
Olinishi H, Takahara J and Irino S: Antisense Src expression inhibits
126
tyrosine phosphorylation of Shc and its association with Grb2 and Sos which
leads to MAPkinase activation in U937 human leukemia ceils. Leukemia 11:
497-503, 1997.
65. Rocic P, Govindarajan G, Sabri A and Lucchesi P: A role for PYK2 in
regulation of ERK1/2 MAP kinases and PI-3Kinase by Ang II in vascular
smooth muscle. Am JPhysioÏ Ceil PhysioÏ 280: C90-C99, 2001.
66. fruman DA, Meyers RE and Cantley LC. Phosphoinositide kinases. Annu
Rev Biochem 67: 48 1-507, 199$.
67. Kandel ES and Hay N. The regulation and activities of the multifunctional
serine/threonine kinase Akt/PKB. Exp CelÏ Res 253: 2 10-229, 1999.
68. Katso R, Okkenhaug K, Ahmadi K, White S, Timm SJ and Waterfield MD.
Cellular function of phosphoinositide 3-kinases: implications for
development, homeostasis, and cancer. Annu Rev Ccli Dey BioÏ 17: 615-75,
2001.
69. Rameh L.E and Cantley L.C. The role of phosphoinositide 3-kinase lipid
products in ceil ffinction. JBioÏ Chem 274: 8347-8350, 1999.
70. Leevers SJ, Vanhaesebroeck B and Waterfield MD. Signaling through
phosphoinositide 3-kinases: the take centre stage. Curr Opin Ccli Biol 11:
219-225, 1999.
71. Vanhaesebroeck B and WaterfieÏd MD. Signaling by distinct classes of
phosphoinositide 3-kinases. Exp C’eilRes 253: 239-254, 1999.
127
72. Chan Tang O, Rittenhouse Susan E and Tsicblis Phuip N: AktIPKB and
other D3 Phosphoinositide-regulated kinases. Annu Rev Biochem 6$: 965-
1014, 1999.
73. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Sairnon M and
Lord 1M. Serine/threonine protein kinases and apoptosis. Exp Ceti Res 256:
34-4 1, 2000.
74. Coffer PJ, Jin J and Woodgett JR. Protein kinase B (c-Akt): a
multifunctional mediator ofphosphoinositide 3-kinase. Biochem J 335: 1-13,
1998.
75. Datta SR, Brunet A and Greenberg ME. Cellular survival: a play in three
Akts. Genes andDev 13: 2905-2927, 1999.
76. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase
signaling. Mol Pharmacol 57: 652-658, 2000.
77. Cardone MII, Roy N, Stennicke HR, Salvesen GS, franke T, Stanbridge E,
frisch S and Reed JC. Regulation of ceil death protease caspase-9 by
phosphorylation. Science 282: 1318-1321, 1998.
7$. Cross DA, Aless DR, Cohen P, Andje&ovich M and I-lemmings BA.
Inhibition of gÏycogen synthase kinase-3 by insulin mediated by protein
kinase B. Nature 378: 785-789, 1995.
79. Kawanabe Y, Hashimoto N and Masaki T. Involvements of voltage
independent Ca2 channels and phosphoinositide 3-kinase in endothelin-1-
induced Pyk2 tyrosine phosphorylation. Mol Pharmacot 63: $0$-$13, 2003.
128
$0. Valks DM, Cook SA, Pham FH, Morrison PR, Cierk A and Sugden PH.
Phenylephrine promotes phosphoiylation of Bad in cardiac myocytes
through the extraceflular signai-reguiated kinases 1/2 and protein kinase A. J
Mol CeÏÏ C’ardiol 34: 749-63, 2002.
81. Pinto-Sietsma SJ and Paul M. A role for endothelin in the pathogenesis of
hypertension: fact or fiction? Kidney Int 67: S115-S121, 199$.
$2. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am
JHypertens 14: $3$-$9$, 2001.
83. Schiffrin EL, Deng LY, Sventek P and Day R. Enhanced expression of
endothehn- 1 gene in resistance arteries in severe human essential
hypertension. JHypertens 15: 57-63, 1997.
$4. Hfrata Y, Takagi Y, Fukuda Y and Harumo f. Endothelin is a potent
mitogen for rat vascular smooth muscle celis. Artherosclerosis 78: 225-228,
1989.
$5. Bobik A, Grooms A, Mifiar JA, Mitcheli A and Grinpukel S. Growth factor
activity of endothelin on vascular smooth muscle. Am J Physiol 258: C408-
C415, 1990.
$6. Ehjovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR and Schiffiin
EL. Regulation of Plasma Endothelin by Sait in Sait-Sensitive Hypertension.
Circulation 103: 263-268, 2001.
87. Schifflin EL. Endothelin: Potential role in hypertension and vascular
hypertrophy. Hypertension 25: 1135-1143, 1995.
129
$8. Luscher Tf, Seo BG and Buhier FR. Potential role of endothelin in
hypertension. Controversy on endothelin in hypertension. Hypertension 21:
752-7, 1993.
$9. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T and Harris RC.
Mesangial celi, glomerular and renal vascular responses to endothelin in the
rat kidney. Elucidation of signal transduction pathways. J Clin Invest 83:
336-42. 1989.
90. Suzuki N, Miyauchi T, Tomobe Y, Matsumoto H, Goto K, Masaki T and
Fujino M. Plasma concentrations of endothelin-1 in spontaneously
hypertensive rats and DOCA-salt hypertensive rats. Biochem Biophys Res
Commun 30: 941-7, 1990.
91. Lariviêre R, Thibault G and Schiffiin EL. Increased endothelin- 1 content in
blood vessels of deoxycorticosterone acetate-sait hypertensive but flot in
spontaneously hypertensive rats. Hypertension 21: 294-300, 1993.
92. Park 313 and Schiffrin EL. ET-A antagonist prevents blood pressure
elevation and vascular hypertrophy of resistance arteries in aldosterone
infused rats. Hypertension 36: 724, 2000.
93. Schiffrin EL, Larivière R, Li JS, Sventek P and Touyz RM.
Deoxycorticosterone acetate plus salt induce overexpression of vascular
endothelin- 1 and severe vascular hypertrophy in spontaneously hypertensive
rats. Hypertension 25: 769-773, 1995.
130
94. D’Uscio LV, Barton M, Shaw S, Moreau P and Luscher TF. Structure and
function of small arteries in salt-induced hypertension: effects of cbronic
endothelin-subtype-A-receptor blockade. Hypertension 30: 905-9 11, 1997.
95. Sventek P, Turgeon A, Garcia R and Schiffiin EL. Vascular and cardiac
overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt
hypertensive rats but only in the late phase of two-kidney one clip Goldblatt
hypertension. JHypertens 14: 57-64, 1996.
96. Sharifi AM, He G, Touyz RM and Schiffrin EL. Vascular endothelin-1
expression and effect of an endothelin ETA antagonist on structure and
ffinction of small arteries from stroke-prone spontaneously hypertensive rats.
JCardiovasc Pharmacol 31: S309-S312, 199$.
97. Day R, Larivière R and Schiffrin EL. In situ hybridization shows increased
endothelin-1 mRNA levels in endothelial ceils of blood vessels of
deoxycorticosterone acetate-sait hypertensive rats. Am J Hypertens 8: 294-
300, 1995.
9$. Larivière R, Sventek P and Schiffiin EL. Expression of endothelin-1 gene in
blood vessels of aduit spontaneously hypertensive rats. Lfe Sel 56: 1889-
1896, 1995.
99. Cargnelli G, Rossi G, Bova S and Pessina AC. In vitro vascular reactivity to
endothelin: a comparison between young and old normotensive and
hypertensive rats. Clin Exp Hypertens A 12: 1437-1451, 1990.
100. Deng LY and Schiffiin EL. Effects of endothehn on resistance arteries of
DOCA-sait hypertensive rats. Am JPhysiol 262: 111782-7, 1992.
131
101. Schiffrin EL, Larivière R, Li JS, Sventek P and Touyz RM. Endothelin-1
gene expression and vascular hypertrophy in DOCA-sait hypertension
compared to spontaneously hypertensive rats. Clin Exp Pharmacol Physiol
22: 5188-90, 1995.
102. Deng LY and Schiffiin EL. Effects of endothelin-Y and vasopressin on
resistance arteries of spontaneously hypertensive rats. Am J Physiol 5: 817-
$22, 1992.
103. Hasdai D and Lerman A. The atherogenic potential of endothelin.
Coronary arteiy Dis 6: 90 1-4, 1995.
104. Griendiing KK and Alexander RW. Endotheial control of the
cardiovascular system. FASEB J 10: 283-92, 1996.
105. Lermai A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM and
Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in
advanced atherosclerosis. NEngÏJMed 325: 997-1001, 1991.
106. Dagassan PH, Breu V, Clozel M, Kunzïi A, Vogt P, Turina M, Kiowski W
and Clozel W. Up-regulation of endothelin-B receptors in atherosclerotic
human coronary arteries. J Cardiovasc Pharmacol 27: 147-53, 1996.
107. Bacon CR, Cary NR and Davenport AP. Endothelin peptide and receptors
in human atherosclerotic coronary artery and aorta. Circ Res 79: 794-801,
1996.
108. Rossi GP, Colonna S, Pavan E, Albertin G, Defla Rocca f, Gerosa G,
Casarotto D et al. Endothelin- I and its mRNA in the wall layers of human
arteries ex vivo. Circulation 99: 1147-55, 1999.
I—,
Ii
109. Ihling C, Lippoldt A, Wessels S, Paul M, Schaefer HE and Zeiher AM.
Endothelin- 1 -like immunoreactivity in human atherosclerotic coronary
tissue: a detailed analysis of the cellular distribution of endothelin-1. J
Pathol 179: 303-8, 1996.
110. Kohno M, Yokokawa K. Yasunari K, Kano H, Minami M and Yoshikawa
J. Effect of the endothelin family of peptides on human coronary artery
smooth-muscle ceil migration. J Cardiovasc Pharmacol 31: S $4-9, 199$.
111. Browatzki M, Schmidt J, Kubler W and Kranzhofer R. Endothelin-1
induces interleukin-6 release via activation of the transcription factor Nf
kappaB in human vascular smooth muscle ceils. Basic Res Cardiol 95: 9$-
105, 2000.
112. Lunec J and Winyard P. Reactive oxygen species: associated pathology. J
Int fed Clin Chem 10: 42-44, 1998.
113. Turrens JF. Superoxide production by the mitochondrial respiratory chain.
BiosciRep 17: 3-8, 1997.
114. Griendling KK and Ushio-fukai M. NADH!NADPH oxidase: role in
cardiovascular biology and disease. Cire Res 86: 494-50 1, 2000.
115. Blanc A, Pandey NR and $rivastava AK. $ynchronous activation of ERK
1/2, p38mapk and PKB/Akt signaling by H202 in vascular smooth muscle
ceils: potential involvement in vascular disease. Int J Mol Med 11: 229-234,
2003.
I •7’
f j)
116. Koshkin V and Pick E. Generat ion of superoxide by purffied and
relipidated cytochrome b559 in the absence of cytosolic activators. FERS
Lett 327: 57-62, 1993.
117. Heyworth PG, Curnutte IT, Nauseef WM, Volpp BD, Pearson DW, Rosen
H ami Clark RA. Neutrophi] nicotinamide adenine dinucleotide phosphate
oxidase assembly. Transiocation of p47-phox and p67-phox requires
interaction between p47-phox and cytochrome b55$. J Clin Invest $7: 352-
356, 1991.
11$. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ and Morawietz H.
EndotheUn- 1 induces NAD(P)H oxidase in human endothelial ceils.
Biochem Biophys Res Commun 269: 713-717, 2000.
119. Wedgwood S, Dettman RW and Black SM. ET-1 stimulates puknonary
arterial smooth muscle cd proliferation via induction of reactive oxygen
species. Am JPhysioÏ Lung CeÏÏ Mol Physiol 2$ 1: Li 05$-Li 067, 2001.
120. Li L, Fink GD, Watts 5W, Northcott CA, Galligan JJ, Pagano PJ and Chen
AF. Endothehn-1 increases vascular superoxide via endotheUn(A)-NADPH
oxidase pathway in low-renin hypertension. Circulation 107: 1053-1058,
2003.
121. Sundaresan M, Yu ZX, Ferrans VJ, Irani K and Finkel T. Requfrernent for
generation of H202 for platelet-derived growth factor signal transduction.
Science 270: 296-299, 1995.
122. GriendUng KK and Alexander RW. Oxidative stress and cardiovascular
disease. Circulation 96: 3 264-5, 1997.
li
123. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendiing
KK and Harrison DG. Angiotensin I1-mediated hypertension in the rat
increases vascular superoxide production via membrane NADHINADPH
oxidase activation. Contribution to alterations of vasomotor tone. J Clin
Invest97: 1916-23, 1996.
124. Warnhoitz A, Nickening G, Schuiz E, Macharzina R, Brasen JH,
Skatchkov M, Heitzer T, Stasch W, Griendiing KK, Harrison DG, Bohrn M,
Meinertz T and Munzel T. Increased NADH-oxidase-mediated superoxide
production in the eariy stages of atherosclerosis: evidence for involvement of
the renin-angiotensin system. Circulation 99: 2027-33, 1999.
125. Cheng T1-I, Shih NL, Chen SY, Wang DL and Chen JJ. Reactive oxygen
species modulate endothelin-1-induced c-fos gene expression in
cardiomyocytes. Cardiovasc Res 41: 654-662, 1999.
126. Liu SL, Lin X, Shi DY, Cheng J, Wu CQ and Zhang YD. Reactive oxygen
species stimulated human hepatoma ccli proliferation via cross-taik between
PI-3 K/PKB and JNK signaling pathways. Arch Biochem Biophys 406: 173-
82, 2002.
127. Cheng CM, Hong HJ, Liu JC, Shih NL et al. Crucial role of extraceilular
signal-regulated kinase pathway in reactive oxygen species-mediated
endothelin- I gene expression induced by endothelin- 1 in rat cardiac
fibroblasts. Mol Pharmacol 63: 1002-1011, 2003.
12$. Fei J, Viedt C, Soto U, Elsing C, Jahn L and Kreuzer J. Endothelin-1 and
smooth muscle celis: induction of jun amino-terminal kinase through an
I.,
Ii
oxygen radical-sensitive mechanism. A rterioscter Thromh Vase Biol 20:
1244-1249, 2000.
129. Frank GD, Motley ED, Inagami T and Eguchi S. PYK2/CAKbeta
represents a redox-sensitive tyrosirie kiiase in vascular srnooth muscle ceils.
Biochem Biophys Res Commun 270: 761-765, 2000.
130. Lloyd-Jones DM and Bloch KD. The vascular biology of nitric oxide and
its rote in atherogenesis. Annu Rev fIzfed 47: 365-375, 1996.
131. Buchwalow lB, Podzuweit T, Bocker W, Samoilova VE, Thonms S,
Wellner M et al. Vascular smooth muscle and nitric oxide synthase. FA$EB
J 16: 500-508, 2002.
132. Kurowska EM. Nitric oxide therapies in vascular diseases. Cïtrr Pharm
Des 8: 155-66, 2002.
133. Marletta MA. Nitric oxide synthase : aspects concerning structure and
catalysis. Cet! 78 : 927-930, 1994.
134. Voet D and Voet JG. Biochemistîy (2’ ed.), John Wiley & Sons, Inc., Ch.
34: 1288-1291, 1995.
135. Raman CS. Li H, Martasek P, Kral V, Masters BS and Poulos TL. C;ystal
structure of constitutive endothelial nitric oxide synthase: a paradigm for
pterin ftmction iiwolving a novel metal center. Ceil 95: 93 9-950, 1998.
136. Mohaupt MG, Elzie iL, Mm KY, Clapp WL, Wilcox CS and Kone BC.
Differential expression and induction of rnRNAs encoding two inducible
nitric oxide synthases in rat kidney. Kidney Int 46: 653-65, 1 994.
1,
Ii
137. Lincoln 1M, Dey N and Sellak 1-1. cGMP-dependent protein kinase
signaling mcchanisms in srnooth muscle: from thc regulation of toue to gene
expression. JAppi Physiol 91: 1421-30, 2001.
138. Traylor 1G and Sharma VS. Why NO? Biochemistiy 31: 2847-9, 1992.
139. Murad F. The nitric oxide-cyclic GMP signal transduction system for
intracellular and intercellular communication. Recent Prog Hormone Res 49:
239-48, 1994.
140. Ortega Matco A and Amaya Aleixandre de Artinano. Nitric oxide
reactivity and mechanisrns involved in its biological effects. Pharmacol Res
42: 42 1-427, 2000.
141. f4jii H, Ichimori K, Hoshiai K and Nakazawa H. Nitric oxide inactivates
NADPH oxidase in pig neutrophils by inhibiting its assembling process. J
Biol Chem 272: 32773-8, 1997.
142. Marletta MA and Spiering MM. Trace elements and nitric oxide ftmction.
JNutr 133: 1431S-1433S, 2003.
143. Eigenthaler M, Lohmann SM, Walter U and Pilz RB. Signal transduction
by cGMP-dependent protein kinases and thefr emerging roles in the
regulation of ccli adhesion and gene expression. Rev Physiol Biochem
Pharmacol 135: 173-209, 1999.
144. Holinann F, Ammcndoia A and Schlossmann J. Rising behind NO:
cGMP-dependent protein kinases. J Ccli $ci 113: 1671-1676, 2000.
145. Denninger JW and Marletta MA. Guanylate cyclase and the .NO/cGMP
signaling pathway. Biochiin Biophys Acta 1411: 334-350, 1999.
1-,
I-,
146. Koesling D, Harteneck C, Humbert P, Bosscrhoff A, Frank R, Schultz G
and Bohme E. The primary structure of the larger subunit of soluble
guanylyl cyclase from bovine lung. Homology betwcen the two subunits of
the enzyme. FERS LeU 266: 12$-132, 1990.
147. Nakane M, Arai K, Saheki S, Ktmo T, Buechier W and Murad F.
Molecular cloning and expression of cDNAs coding for soluble guanylate
cyclase from rat lung. JB1o1 Chem 265: 16841-16845, 1990.
14$. Yu 5M, Hung LM and Lin CC. cGMP-elevating agents suppress
proliferation of vasccLlar smooth muscle ceils by hihibiting the activation of
epidermal growth factor signaling pathway. CircttÏation 95: 1269-77, 1997.
149. Yu SM, Tsai $Y, Kuo SC and Ou JT. Inhibition of platelet function by
A02 131-1, a novel inhibitor of cGMP-specific phosphodiesterase, in vitro
and in vivo. BÏood 87: 3758-3767, 1996.
150. $hahid M, van Amsterdam RG, de Boer J, Berge RE, Nicholson CD and
Zaagsma J. The presence of five cyclic nucleotide phosphodiesterase
isoenzyme activities in bovine tracheal smooth muscle and the functional
effects ofselective inhibitors. Br JPharrnacoÏ 104: 471-477, 1991.
151. Yu SM, Cheng ZJ and Kuo SC. Endotheium-dependent relaxation of rat
aorta by butein, a novel cyciic AMP-specilic phosphodiesterase inhibitor.
EttrJPharmacoÏ 280: 69-77, 1995.
152. D’souza FM, Sparks Ri, Chen H, Kadowitz PJ and Jeter JR Jr.
Mechanism of eNOS gene transfer inhibition of vascular smooth muscle ccli
proliferation. Am JPhysiol CeÏl Physiol 284: C191-C199, 2003.
li
153. Schmidt 1-II-111W and Walter U : NO at work. CeÏÏ 78: 919-925, 1994.
1 54. Sandirasegarane L. Charles R. Bourbon N and Kester M. NO regulates
PDGF-induced activation of PKB but not ERK in A7r5 ceils: implications
for vascular growth arrest. Am J FhyioÏ Cell Fhvsiol 279: C225-C235.
2000.
155. Wang D. Yu X and Brecher P. Nitric oxide inhibits ATT-induced activation
of the calcktm-sensitive tyrosine kinase proline-rich tyrosiiie kinase 2
without affecting epidermal growth factor receptor transactivation. .1 Biol
Chem 274: 24342-24348, 1999.
156. Wever R. Stroes E and Rabelink TJ. Nitric oxide and
hvpercholesterolernia: a malter of oxidation and reduction? Atherosclerosis
137: S51-60, 199$.
1 57. Alfke I-I, Kleb B and Kiose KJ. Nitric oxide inhibits the basic fibroblast
growth factor-stimu]ated migration of bovine vascular srnooth muscle ceils
in vitro. VASA 29: 99-102, 2000.
158. failli P. Defranco RM, Caligiuri A. Gcntilini A, Romanelli RG, Marra F,
Batignani U et al. Nitrovasodilators inhibit platelet-derived growth factor
induccd proliferation and migration of activated hurnan hepatic stdllate cells.
Gastroenterology 119: 479-492. 2000.
159. Ni CW. Wang DL, Lien SC. Cheng JJ. Chao YJ and Hsieh HJ. Activation
of PKC-epsilon and ERKI/2 participates in shear-induced endothelial MCP
I expression that is repressed by nitric oxide. J Ccli Physiol 195: 428-434,
r n-’
Lu’)-,.
li
160. Taimor G. Rakow A and Piper HM. Transcription activator protein I (AP
1) mediates NO-induced apoptosis of aduit eardiomyocytes. FA$EB J 15:
2518-20, 2001.
161. Nishida E and Gotoli Y. The MAP kinase cascade is essential for diverse
signal transduction pathways. Trends PharmacoÏ Sel 1$: 128-131. 1993.
162. Zhang YM, Wang KQ, Zhou GM. Zuo J and Ge JB. Endothelin-1
promoted proliferation of vascular smooth muscle ccli through pathway of
extracellular signal-regulated kinase and cyclin Dl. Acta Pharmacol 5m 24:
563-8, 2003.
163. Yoshizurni M, Kim S. Kagarni S. Hamaguchi A. Tsuehiya K. Houchi H,
Iwao H, Kido H and Tamaki T. Effect ofendothelin-1 (1-3 1) on extracellular
signal-reguiated kinase and proliferation of human coronary artery smooth
muscle celis. Br,JFharmaeol 125: 10 19-1027, 1998.
164. Cornwel] TL, Arnold E, Bocrth NJ and Lincoin TM. Tnhibition of smooth
muscle ccli growth by nitric oxide and activation of cAMP-dependent
protein kinase by cGMP. Am .1 PhvsioÏ Cd Physiol 267: C1405-C1413,
1994.
165. Paolocci N, Ekelund UE, Isoda T. Ozaki M, Vandegaer K et al. cGMP
independent inotropic effects of nitric oxide and peroxynitrite donors:
potential role for nitrosylation An, J Physiol Jfeart Cire Phvsioi 279:
I-11982-$8, 2000.
166. Lahteenmaki T. Sievi E and Vapaatalo 1-I. Inhibitory efYects of mcsoionic
3-aryl substituted oxatriazole-5-imine dcrivativcs on vascular smooth muscle
140
oeil milogenesis and prolikration in vitro. & J Pharmacol 125: 402408,
1998.
167. flan CD anti Pan JY. Nitric oxide inMbits tbc exprcssion of pmto
oncogene c-fos hiduced angiotensin II and endothclin-1 in
cardiomyocytes. Sheng Li Xue Bao 52:450,2000.
162. Wang D, Yu X and Brecher P. Nitric oxidc and N-acctykystehr inMbk
flic activation of ndtogen-actfrated protein kinases by angiotensin U in ni
cardiac fibroblasta. JBlol Client 273:33027-33034, 1998.
169. Boerth Ni, Dey NB, Comweil U and Lincohi TM. Cyclic GMP
depcndent protein kinase regulates vascular smooth muscle ccli phenotype. J
Vaw Rets 34:245-259, 1997.
170. Wang L and Proud CG. RaWERK signaling is essential for activation of
protein synthesis by Gq protcin-coupled receptor agonisa in aduh
cardiomyoc$es. Circ Rets 91:821-9,2002.
171. Sugdcn PU, Fufler Si, Mynett iii, Hatchett Ri, Bogoyevkch MA anti
Sugden MC. Stimulation of aduh ni ventricular myocyte protein synthcsis
and phosphoinoshide hydrolysis by flic endoihclins. Biochim Biophys Ada
1175: 327-32, 1993.
172. Bogoyevitch MA, Glennon PE, Andcrsson MB, Ckrk A, Tszou A,
Marshafl CJ, Parker PJ and Sugden PH. Endothelin-1 and fibroblasts growth
&cton siimiitate thc mitogen-activatcd protein kinase signaling cascade in
cardiac myocytes. The potential mie ofilie cascade in tir inwgration oftwo
141
signaling pathways leading te myocyte hypertrophy. .1 Biol Chem 269: 111 0-
1110 100/1
173. Yambolicv lA. Nrubv A and Gerthoflèr WI. Endothelin-1 actieatesMAP
kinases and c—Jun in puhnonary artery smooth muscle. Pulm Pharmaco!
T1,,,,,.11.)flÇ)flQ 100Q
174. Clerk A and Sueden P. Reculation of nhosnholinase C and I) in rat
ventricular mvocvtes: stimulation 1w endothelin-1. hradvkinin and
nhenvlenhrine. J Me! (‘e!! Cardiol 29: 1593—1604. 1997.
175. Bac YS. Kane SW Sec MS. Haines IC. Tekie E, Check PH and Rhee SG.
Enidermal erowth lactor (EGfl-induced oeneration oC lwdroeen neroxide.
Role in EUF receptor-mediated tyrosine phsophorylatio” ‘ Bio! (‘hem 272:
217-1. 1997
176. Griendline KK. Minieri CA. O!lerenshaw il) and Alexander RW.
Anciotensin II stimulates NAI)H and NAL)P1 I oxidase activitv in cu!tured
vascular smooth usele cells Car Rps 74: 1141-1 14 1994rn
177. Le YY Weng JM and Cruz IF. Reactive oxygen species mediate cytokine
activation of c-Ion N112-terminal kinases. J Bio! (‘hem 271: 15703-1 5707.
1 flt
178. Takicawa T, Go M, Chobanian AV and Brecher P. ElTect of nitric oxide
on DNA renticatien induced bv anujetensm 11 in rat cardiac fjhrob!asts.
Hvoerlension 30: lf)35-40. 1997.
142
179. Ileller R. Po]ack T. Grabner R and Till U. Nitric oxide inhibits
pre1ilration ef human endothelial cells via a mechanism independent of
cGMP. Atherosclerosis 144: 49-57. 1999.
180. Sandirascearane L and Diamond J. The nitric oxide donors. SNAP and
DEA1O e’c’1 a ncuaillte ii,otrn1c eficc1 lp ri cardinmîoces ‘ich 1s
indeoendcn ofcclic U4P ete’ niion 1 Â,Irj C eh (rn )Ifj 31 °—8’)8 1 99
181. Lenormand P. Sardet C. Panes G. L’Allemain G. Erunet A and Pouvssegur
J. Growth factors induce nuclear translocation of MAP kinases to42mank
and n44mank) but not of their activai.or MAP kinase kinase (p45mapkk) in
flhrnbk. JG-’ÏI mû! 122: 107Q-XS 1QQ
r
Ç:
